<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004524.pub3" GROUP_ID="MUSKEL" ID="251003050814354573" MERGED_FROM="" MODIFIED="2013-01-24 16:43:12 +0000" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="C050-R" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="8.0">
<COVER_SHEET MODIFIED="2013-01-24 11:08:23 -0500" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<TITLE>Methotrexate for ankylosing spondylitis</TITLE>
<CONTACT>
<PERSON ID="12398" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Junmin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chen</LAST_NAME>
<SUFFIX/>
<POSITION>Director and Professor</POSITION>
<EMAIL_1>drjunminchen@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL>http://www.fyyy.com/</URL>
<MOBILE_PHONE>+86 13489036064</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Hematology and Rheumatology</DEPARTMENT>
<ORGANISATION>The First Affiliated Hospital of Fujian Medical University</ORGANISATION>
<ADDRESS_1>#20 Chazhong Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Fuzhou</CITY>
<ZIP>350005</ZIP>
<REGION>Fujian Province</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 591 87981678</PHONE_1>
<PHONE_2/>
<FAX_1>+86 591 83318716</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-01-24 11:08:23 -0500" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="12398" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Junmin</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Chen</LAST_NAME>
<SUFFIX/>
<POSITION>Director and Professor</POSITION>
<EMAIL_1>drjunminchen@hotmail.com</EMAIL_1>
<EMAIL_2/>
<URL>http://www.fyyy.com/</URL>
<MOBILE_PHONE>+86 13489036064</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Hematology and Rheumatology</DEPARTMENT>
<ORGANISATION>The First Affiliated Hospital of Fujian Medical University</ORGANISATION>
<ADDRESS_1>#20 Chazhong Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Fuzhou</CITY>
<ZIP>350005</ZIP>
<REGION>Fujian Province</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 591 87981678</PHONE_1>
<PHONE_2/>
<FAX_1>+86 591 83318716</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="93906542823429167874100201221444" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Mirella</FIRST_NAME>
<MIDDLE_INITIALS>MS</MIDDLE_INITIALS>
<LAST_NAME>Veras</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Mvera025@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613 562 5800 - ext 2509</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12448" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Chao</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Liu</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>dr_chaoliu@yahoo.com.cn</EMAIL_1>
<EMAIL_2>lcwv@sohu.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>The First Hospital of Hebei Medical University</ORGANISATION>
<ADDRESS_1>Donggang Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Shijiazhuang</CITY>
<ZIP>050031</ZIP>
<REGION>Hebei Province</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 311 85917032</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="DCC6862282E26AA20078D4E67CF08941" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Junfang</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Lin</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>linjunfang1@sina.com</EMAIL_1>
<EMAIL_2/>
<URL>http://www.fyyy.com/</URL>
<MOBILE_PHONE>+86 13809552545</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Hematology and Rheumatology</DEPARTMENT>
<ORGANISATION>The First Affiliated Hospital of Fujian Medical University</ORGANISATION>
<ADDRESS_1>Chating</ADDRESS_1>
<ADDRESS_2/>
<CITY>Fuzhou</CITY>
<ZIP>350005</ZIP>
<REGION>Fujian</REGION>
<COUNTRY CODE="CN">China</COUNTRY>
<PHONE_1>+86 591 87982510</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-11-20 11:11:58 -0500" MODIFIED_BY="Junmin Chen">
<UP_TO_DATE>
<DATE DAY="20" MONTH="11" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="25" MONTH="6" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="3" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW MODIFIED="2012-07-19 04:32:17 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2011-07-04 16:57:23 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="7" YEAR="2011"/>
<DESCRIPTION>
<P>Change in authorship.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-07-19 04:32:17 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="4" MONTH="7" YEAR="2011"/>
<DESCRIPTION>
<P>New search but no new studies included.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-07-04 16:56:09 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2011-07-04 16:56:09 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
<P>CMSG ID: C050-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2011-03-24 11:57:34 -0400" MODIFIED_BY="Junmin Chen">
<INTERNAL_SOURCES MODIFIED="2011-03-24 11:51:55 -0400" MODIFIED_BY="Junmin Chen">
<SOURCE MODIFIED="2011-03-24 11:51:55 -0400" MODIFIED_BY="Junmin Chen">
<NAME>The First Affiliated Hospital of Fujian Medical University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2011-03-24 11:57:34 -0400" MODIFIED_BY="Junmin Chen">
<SOURCE MODIFIED="2011-03-24 11:57:34 -0400" MODIFIED_BY="Junmin Chen">
<NAME>Science development fund, Fujian Medical University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-24 11:16:03 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-01-22 09:38:54 -0500" MODIFIED_BY="[Empty name]">
<TITLE>Methotrexate for ankylosing spondylitis</TITLE>
<SUMMARY_BODY MODIFIED="2013-01-22 09:38:54 -0500" MODIFIED_BY="[Empty name]">
<P>Researchers in the Cochrane Collaboration conducted a review about the effect of the drug methotrexate in people with ankylosing spondylitis (AS). They identified three studies, which included 116 participants, that met the inclusion criteria.</P>
<P>
<B>The review shows that for people with AS:</B>
</P>
<P>- methotrexate probably improves physical function but this may have happened by chance.</P>
<P>- it is uncertain whether methotrexate will help to ease pain, tenderness, and swelling in the ligaments of the joints, movement of the spine, stiffness, or overall well-being because there were not enough participants studied.</P>
<P>- it is uncertain whether methotrexate slows damage to the joints because the studies did not look at an x-ray of the spines of the people with AS.</P>
<P>We often do not have precise information about side effects and complications. This is particularly true for rare but serious side effects. Possible side effects include stomach problems, mild headaches, mouth sores, changes in liver function, hair loss, or mild infections. Rare complications may include lung problems. It is important to keep medical appointments to catch any serious problems early. </P>
<P>
<B>What is AS and what is methotrexate? </B>
</P>
<P>AS is a type of arthritis that usually occurs in the joints and ligaments of the spine. It may also affect the shoulders, hips, or other joints. Pain and stiffness occurs and limits movement in the back and in other joints that are affected.</P>
<P>Methotrexate (MTX) is a disease-modifying antirheumatic drug (DMARD). It is the most commonly used DMARD in people with inflammation in their joints. It works to control inflammation in affected joints to stop the pain and stiffness. MTX is taken once per week and may be administered in pill form or as an injection.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-24 11:16:03 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-01-22 09:27:10 -0500" MODIFIED_BY="Junmin Chen">
<P>Ankylosing spondylitis (AS) is a chronic inflammatory disease of unknown cause, characterized by sacroiliitis and spondylitis. Methotrexate (MTX), a widely used disease-modifying antirheumatic drug (DMARD), is effective for rheumatoid arthritis (RA), and so might work for AS. This is an update of a Cochrane review first published in 2004, and previously updated in 2006.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-07-19 04:32:48 -0400" MODIFIED_BY="Junmin Chen">
<P>To evaluate the benefits and harms of MTX for treating AS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-07-27 10:18:28 -0400" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (The Cochrane Library Issue 6, 2012), MEDLINE (2005 to June 25, 2012), EMBASE (2005 to June 25, 2012), Ovid MEDLINE Scopus, World Health Organization International Clinical Trials Registry Platform and the reference sections of retrieved articles. Trials published in any language were acceptable. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-01-22 09:27:52 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials (RCTs) and quasi-randomized controlled trials (qRCTs) examining the benefits and harms of MTX versus placebo, other medication, or no medication for treatment of AS.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-01-22 09:28:15 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors independently extracted data and assessed risk of bias. We resolved any disagreements through discussions with a third review author. In the absence of significant heterogeneity, we combined results for continuous data using mean difference or standardized mean difference values. We calculated the risk ratio for dichotomous data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-01-24 11:16:03 -0500" MODIFIED_BY="Junmin Chen">
<P>We identified three RCTs (no additional new studies), which included 116 participants. Of these three trials, one was a 12-month trial that compared naproxen plus MTX with naproxen alone. Also, there were two 24-week trials that compared different doses of MTX with placebo. We included the outcomes of response, physical function, pain, spinal mobility, peripheral joints/entheses pain, swelling and tenderness, changes in spine radiographs, and patient and physician global assessment. We judged only one trial to be at low risk of bias. Across these three trials, we did not identify any statistically signi&#64257;cant differences favoring MTX treatment over no MTX treatment apart from one exception. The response rate in one trial showed a statistically significant absolute benefit of 36% and a number to treat for benefit (NNT) of three in the MTX group compared to the placebo group (RR 3.18, 95% CI 1.03 to 9.79). This response rate was based on a composite index that included assessments of morning stiffness, physical well-being, Bath ankylosing spondylitis disease activity index (BASDAI), Bath ankylosing spondylitis functional index (BASFI), health assessment questionnaire for spondyloarthropathies (HAQ-S), and physician and patient global assessment. We did not identify any outcome that showed a statistically significant difference between the MTX treated and no MTX treatment groups when endpoint results were compared. Furthermore, no serious side effects were reported in any of the included trials.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-01-22 09:30:16 -0500" MODIFIED_BY="Junmin Chen">
<P>There is not enough evidence to support any benefit of MTX in the treatment of AS. High-quality RCTs of larger sample sizes are needed to clarify the effect(s) of MTX on AS.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-01-22 10:12:09 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-01-22 09:41:27 -0500" MODIFIED_BY="[Empty name]">
<P> </P>
<CONDITION MODIFIED="2013-01-22 09:39:53 -0500" MODIFIED_BY="[Empty name]">
<P>Ankylosing spondylitis (AS) is a type of arthritis, i.e. a chronic inflammatory disease of unknown cause. Most commonly it occurs in the joints and ligaments of the spine, although it may also affect the shoulders, hips, and other joints. As a result, the condition is characterized by sacroiliitis and spondylitis, i.e. pain, stiffness, and limited movement in the back and other affected joints. AS can come and go, last for long periods, and can be quite severe. Depending on the geographical region, the prevalence of AS can range from 0.1% to 1.4% of the population (<LINK REF="REF-Akkoc-2005" TYPE="REFERENCE">Akkoc 2005</LINK>). People with AS can have a significant reduction in quality of life and an increased mortality rate. Furthermore, AS has a considerable impact on healthcare costs and also affects workforce participation (<LINK REF="REF-Annelies-2006" TYPE="REFERENCE">Annelies 2006</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-01-22 09:41:05 -0500" MODIFIED_BY="[Empty name]">
<P>Non-steroidal anti-inflammatory drugs (NSAIDs) are the cornerstone of pharmaceutical treatment. For patients refractory or intolerant to NSAIDs, conventional disease-modifying antirheumatic drugs (DMARDs) such as gold salts, antimalarial drugs, methotrexate, D-penicillamine, sulfasalazine, and various immunosuppressive treatments are used. However, the benefits of DMARDs are unclear except for sulfasalazine, which was found to improve peripheral joint inflammation (<LINK REF="REF-Chen-2005" TYPE="REFERENCE">Chen 2005</LINK>). Anti-TNF agents, including adalimumab, etanercept, and infliximab, have proven considerably effective (<LINK REF="REF-McLeod-2007" TYPE="REFERENCE">McLeod 2007</LINK>) but the latter's expense means that few patients can access these drugs.</P>
</INTERVENTION>
<THEORY MODIFIED="2013-01-22 09:41:15 -0500" MODIFIED_BY="[Empty name]">
<P>Methotrexate (MTX) is currently one of the most widely used DMARDs. Its benefit in patients with rheumatoid arthritis (RA) has been confirmed by several well-designed randomized controlled clinical trials (RCTs) (<LINK REF="REF-Suarez_x002d_Almazor-2003" TYPE="REFERENCE">Suarez-Almazor 2003</LINK>; <LINK REF="REF-Katchamart-2010" TYPE="REFERENCE">Katchamart 2010</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-01-22 09:41:27 -0500" MODIFIED_BY="[Empty name]">
<P>There is uncertainty whether MTX is an effective drug for treatment of AS. We performed a systematic review in 2003 and this is an update of the original review.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-01-22 09:41:51 -0500" MODIFIED_BY="[Empty name]">
<P>To evaluate the benefit and toxicity of MTX for the treatment of AS by comparing MTX versus placebo; MTX versus other medication; and MTX versus no medication.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-01-22 09:51:20 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-01-22 09:45:34 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-01-22 09:42:10 -0500" MODIFIED_BY="[Empty name]">
<P>We evaluated RCTs and quasi-RCTs (qRCTs) examining the benefits and harms of MTX on AS.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-01-22 09:42:45 -0500" MODIFIED_BY="[Empty name]">
<P>We included patients with AS fulfilling one of the following or other criteria: 1961 Rome, 1966 New York, modified 1984 New York, Amor, or European Spondylarthropathy Study Group (ESSG) criteria (<LINK REF="REF-Olivieri-2002" TYPE="REFERENCE">Olivieri 2002</LINK>). Furthermore, we included studies with a mixture of spondyloarthropathies/spondyloarthritis patients and participants were included if data assessing the outcomes specific to patients with AS were available. Regarding inclusion of participants, we had no age or sex restrictions. Also, we included patients with or without the impairment of peripheral joints.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-05-23 10:54:47 -0400" MODIFIED_BY="Junmin Chen">
<P>MTX given orally or intramuscularly for at least 12 weeks. We included the following comparisons:<BR/>1. MTX versus placebo;<BR/>2. MTX versus other medication;<BR/>3. MTX versus no medication.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-01-22 09:45:34 -0500" MODIFIED_BY="[Empty name]">
<P>Based on the core set for the evaluation of disease-controlling antirheumatic treatment (DC-ART) proposed by Assessment of Ankylosing Spondylitis (ASAS) Working Group (<LINK REF="REF-van-der-Heijde-1999" TYPE="REFERENCE">van der Heijde 1999</LINK>; <LINK REF="REF-van-der-Heijde-2002" TYPE="REFERENCE">van der Heijde 2002</LINK>), we included the following outcomes:</P>
<SUBSECTION>
<HEADING LEVEL="4">Major outcomes</HEADING>
<OL>
<LI>ASAS 40 (<LINK REF="REF-van-der-Heijde-2002" TYPE="REFERENCE">van der Heijde 2002</LINK>; <LINK REF="REF-van-der-Heijde-2005" TYPE="REFERENCE">van der Heijde 2005</LINK>) or ASDAS major improvement (<LINK REF="REF-Sieper-2009" TYPE="REFERENCE">Sieper 2009</LINK>);</LI>
<LI>Partial remission ( defined as a value of two or less on a scale from 0 to 10 in each of the four domains of the ASAS 20);</LI>
<LI>Bath ankylosing spondylitis function index (BASFI);</LI>
<LI>X-ray of the spine;</LI>
<LI>MRI (spine, or SI joints, or both);</LI>
<LI>Serious adverse events;</LI>
<LI>Withdrawals due to adverse events.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Minor outcomes</HEADING>
<UL>
<LI>Other ASAS responses (<LINK REF="REF-van-der-Heijde-2002" TYPE="REFERENCE">van der Heijde 2002</LINK>; <LINK REF="REF-van-der-Heijde-2005" TYPE="REFERENCE">van der Heijde 2005</LINK>);</LI>
<LI>Disease activity;</LI>
<LI>Physical function;</LI>
<LI>Pain;</LI>
<LI>Spinal mobility and spinal stiffness;</LI>
<LI>Peripheral joints/entheses (pain, swelling, and tenderness);</LI>
<LI>Changes in hip radiograph and MRI;</LI>
<LI>Patient global assessment and physician global assessment;</LI>
<LI>Fatigue;</LI>
<LI>Level of acute phase reactants, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP);</LI>
<LI>Any side effects.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-01-22 09:46:17 -0500" MODIFIED_BY="[Empty name]">
<P>We searched for relevant RCTs and qRCTs in any language for the first version of this Cochrane Review in 2003, using CENTRAL (Cochrane Central Register of Controlled Trials), MEDLINE, EMBASE and CINAHL (see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>). For the second version review in 2006, all searches were updated on November 20, 2005 (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). For this, the third version, we searched CENTRAL (The Cochrane Library Issue 6 of 12, 2012), MEDLINE (2005 to June 25, 2012), EMBASE (2005 to June 25, 2012), CINAHL (2005 to June 25, 2012), Scopus (2005 to June 25, 2012), World Health Organization International Clinical Trials Registry Platform (June 25, 2012) and the reference sections of retrieved articles. We included the full search strategies in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and the number of records retrieved in <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-01-22 09:51:20 -0500" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2013-01-22 09:46:34 -0500" MODIFIED_BY="[Empty name]">
<P>Two authors (JC and MMSV) independently reviewed the full-text trial reports for this review update according to the selection criteria. We resolved any disagreements regarding the inclusion of studies by recourse to a third review author.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-01-22 09:47:01 -0500" MODIFIED_BY="[Empty name]">
<P>We extracted the data from the included trials on a pre-structured data extraction form. Two authors (JC and MMSV) independently entered this data into <LINK REF="REF-Review-Manager-_x0028_RevMan_x0029_" TYPE="REFERENCE">Review Manager (RevMan)</LINK>.</P>
<P>In this review, we only included outcomes that were specified in the previously published protocol. We entered continuous data (e.g. visual analogue scales of pain, patient global assessment) as means and standard deviations (SD), and dichotomous outcomes (e.g. response, improvement) as number of events.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-01-22 09:48:51 -0500" MODIFIED_BY="[Empty name]">
<P>For this review, we assessed risk of bias in all included studies using The Cochrane Collaboration's tool for assessing risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). There were six domains: random sequence generation, allocation concealment, blinding of participants, personnel and outcome assessment, incomplete outcome data, selective reporting and other sources of bias such as baseline imbalance. We made a judgment about each risk of bias domain according to the criteria described in the Cochrane Handbook (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>). We categorized risk of bias as either 'low risk', 'high risk' or 'unclear risk'. Two review authors (JC and MMSV) independently assessed the included trials using a data collection form (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-01-22 09:49:05 -0500" MODIFIED_BY="Junmin Chen">
<P>For continuous data, we used mean difference (WMD) or standardized mean difference (SMD) values depending on the comparability of scales. For dichotomous data, we used risk ratio (RR) values.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-01-22 09:49:09 -0500" MODIFIED_BY="Junmin Chen">
<P>In this review we included only RCTs.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-07-27 10:33:05 -0400" MODIFIED_BY="Junmin Chen">
<P>For continuous data (e.g. visual analogue scales of pain, patient global assessment), we analyzed only the available data. For dichotomous data (e.g. response, improvement), we used intention-to-treat (ITT) analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-01-22 09:49:38 -0500" MODIFIED_BY="Junmin Chen">
<P>We explored heterogeneity by using the Chi<SUP>2</SUP> test with significance set at P &lt; 0.10. We measured the quantity of heterogeneity by using the<I> </I>I<I>
<SUP>2</SUP> </I>statistic, with I<I>
<SUP>2 </SUP>
</I>&gt; 0.50 as substantial heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2013-01-22 09:49:50 -0500" MODIFIED_BY="Junmin Chen">
<P>We planned to use funnel plots to detect publication bias. However, we did not pursue this any further as we identified only three trials that met the inclusion criteria.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2013-01-22 09:50:16 -0500" MODIFIED_BY="Junmin Chen">
<P>We performed meta-analysis using <LINK REF="REF-Review-Manager-_x0028_RevMan_x0029_" TYPE="REFERENCE">Review Manager (RevMan)</LINK>. We used a random-effects model to combine the results where heterogeneity was significant. Otherwise, we used a fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2013-01-22 09:50:32 -0500" MODIFIED_BY="Junmin Chen">
<P>We planned to perform subgroup analyses by characteristics of participants (e.g. different AS classi&#64257;cation criteria, male or female, with or without peripheral arthritis) and intervention (e.g. different dosage, different duration). However, we did not undertake these analyses as these subgroup datasets were not available.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2013-01-22 09:51:20 -0500" MODIFIED_BY="Junmin Chen">
<P>We planned two sensitivity analyses according to whether:</P>
<OL>
<LI>the allocation to intervention or control groups was truly randomized or quasi-randomized, to explore the potential for selection bias;</LI>
<LI>the outcome assessment was blinded, to explore the potential for assessment bias associated with knowledge of the intervention. If either of the sensitivity analyses affected the results of the review, then conservative conclusions would be drawn.</LI>
</OL>
<P>However, we did not perform these sensitivity analyses as the number of trials that met the inclusion criteria was too low.</P>
<SUBSECTION>
<HEADING LEVEL="3">Summary of finding table</HEADING>
<P>We performed grading of the evidence using the GRADE profiler software, which was developed by the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) Working Group (www.gradeworkinggroup.org). A summary of findings table was created in <LINK REF="REF-Review-Manager-_x0028_RevMan_x0029_" TYPE="REFERENCE">Review Manager (RevMan)</LINK>. We presented seven outcomes that were deemed important to patients. They were ASAS40 (or ASDAS major improvement), partial improvement, BASFI, x-ray of spine, MRI (spine, or SI joints, or both), serious adverse events, and withdrawal due to adverse events.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-01-22 10:02:43 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-01-22 09:54:55 -0500" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-01-22 09:52:08 -0500" MODIFIED_BY="[Empty name]">
<P>We obtained 320 records from the updated search (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). Following screening of titles and abstracts, we excluded 313 records. After assessment of full text articles, we identified two records as repeated publications of <LINK REF="STD-Breban-2008" TYPE="STUDY">Breban 2008</LINK> and <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK>. Two studies (<LINK REF="STD-P_x00e9_rez_x002d_Guijo-2007" TYPE="STUDY">Pérez-Guijo 2007</LINK>; <LINK REF="STD-Kabasakal-2009" TYPE="STUDY">Kabasakal 2009</LINK>) were not RCTs. Three trials (<LINK REF="STD-Breban-2008" TYPE="STUDY">Breban 2008,</LINK> <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK> and <LINK REF="STD-Mulleman-2011" TYPE="STUDY">Mulleman 2011</LINK>)examined the efficacy of infliximab. We excluded these trials from the present review because there is a separate Cochrane review that addresses biologics in AS (<LINK REF="REF-Zochling-2005" TYPE="REFERENCE">Zochling 2005</LINK>), according to the Cochrane Musculoskeletal Group (CMSG). Therefore, we did not include any new studies to the previous version review (<LINK REF="REF-Chen-2006" TYPE="REFERENCE">Chen 2006</LINK>), which included three RCTs (<LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK>; <LINK REF="STD-Roychowdhury-2002" TYPE="STUDY">Roychowdhury 2002</LINK>; <LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-01-22 09:53:46 -0500" MODIFIED_BY="[Empty name]">
<P>Among the three included trials, one trial (<LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK>) compared naproxen plus MTX (7.5 mg/week orally) with naproxen alone over a duration of 12 months. Two trials (<LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK>; <LINK REF="STD-Roychowdhury-2002" TYPE="STUDY">Roychowdhury 2002</LINK>) compared MTX with placebo, using MTX doses of either 10 mg/week orally or 7.5 mg/week orally, respectively, for a duration of 24 weeks. In total, 116 participants were included in the trials: 89 males and 27 females. Their mean ages ranged from 32 to 46 years and the mean duration of disease was from 5.7 to 17 years. Between 11.7% and 65% of the participants had peripheral arthritis (i.e. 6/51, 9/30, and 21/35 in the <LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK>, <LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK>, and <LINK REF="STD-Roychowdhury-2002" TYPE="STUDY">Roychowdhury 2002</LINK>, respectively). None of these three studies provided a definition of peripheral arthritis. A total of 55 participants received MTX and 59 did not. We have included further details in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-01-22 09:54:55 -0500" MODIFIED_BY="[Empty name]">
<P>We excluded one trial (<LINK REF="STD-Xie-2003" TYPE="STUDY">Xie 2003</LINK>) because it compared the effects of different dosages of MTX and did not include the comparison specified in the inclusion criteria. Two trials (<LINK REF="STD-P_x00e9_rez_x002d_Guijo-2007" TYPE="STUDY">Pérez-Guijo 2007</LINK>; <LINK REF="STD-Kabasakal-2009" TYPE="STUDY">Kabasakal 2009</LINK>) were not RCTs. Another trial (<LINK REF="STD-Haque-1999" TYPE="STUDY">Haque 1999</LINK>), which treated 32 patients with seronegative spondyloarthropathy, could not be reviewed because of the lack of a full text article. To date, our attempts to contact the authors have been unsuccessful. We excluded three studies (<LINK REF="STD-Breban-2008" TYPE="STUDY">Breban 2008</LINK>; <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK>, <LINK REF="STD-Mulleman-2011" TYPE="STUDY">Mulleman 2011</LINK>) because there is a separate review addressing the biologics in AS (<LINK REF="REF-Zochling-2005" TYPE="REFERENCE">Zochling 2005</LINK>). <LINK REF="STD-Breban-2008" TYPE="STUDY">Breban 2008</LINK> is a multicenter RCT comparing continuous infliximab group with on-demand infliximab group. The on-demand group patients were further randomized into infliximab monotherapy group and infliximab plus MTX group. <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK> is a single center RCT of 38 AS patients, comparing infliximab plus MTX with infliximab plus placebo. <LINK REF="STD-Mulleman-2011" TYPE="STUDY">Mulleman 2011</LINK> is a two-center, open-label, prospective randomized study comparing treatment with infliximab alone and infliximab with MTX.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-01-22 09:58:01 -0500" MODIFIED_BY="[Empty name]">
<P>The risk of bias of included trials varied greatly and we have summarized this in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<ALLOCATION MODIFIED="2013-01-22 09:55:58 -0500" MODIFIED_BY="[Empty name]">
<P>The <LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK> trial was reported as a RCT, but details of the methods of randomization and concealment were not given. Indeed, since one group of patients received naproxen plus MTX and the other received naproxen alone, it is doubtful whether allocation concealment was adequate.The <LINK REF="STD-Roychowdhury-2002" TYPE="STUDY">Roychowdhury 2002</LINK> trial was described as a RCT but the authors did not report the methods of randomization and concealment. <LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK> was reported as a double blind RCT. The randomization was centralized by the coordinating center and was communicated to other centers by fax. Concealment seemed to be adequate.</P>
</ALLOCATION>
<BLINDING MODIFIED="2013-01-22 09:56:09 -0500" MODIFIED_BY="[Empty name]">
<P>All three studies were blinded. In <LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK>, the report stated that the outcome assessment was blinded. However, we are not sure whether the patients and care providers were also blinded. <LINK REF="STD-Roychowdhury-2002" TYPE="STUDY">Roychowdhury 2002</LINK> was described as double-blind but it was unclear who were blinded. In <LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK> trial, patients and researchers were blinded.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-01-22 09:56:58 -0500" MODIFIED_BY="[Empty name]">
<P>For <LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK>, we contacted the trial report author who confirmed that all participants completed the trial and results included all participants. In <LINK REF="STD-Roychowdhury-2002" TYPE="STUDY">Roychowdhury 2002</LINK>, two patients were lost to follow-up but it was unclear to which intervention group they belonged. We attempted to clarify this area of uncertainty by contacting the authors, but to date we have been unsuccessful. The outcomes were presented as individual patient data from which we calculated the summary values. In <LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK> trial, one patient dropped out from the MTX and the placebo group. The reasons given were lack of compliance and lack of response, respectively. For those patients who missed the follow-up, the value was deduced from the previous visit. ITT analysis was used for the primary outcome (response in the composite index).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-01-22 09:57:15 -0500" MODIFIED_BY="[Empty name]">
<P>The protocols were available for all the trials and reports were available for pre-specified outcomes. Therefeore, we scored all three trials at low risk of bias.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-01-22 09:58:01 -0500" MODIFIED_BY="[Empty name]">
<P>In the <LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK> trial, some baseline parameters (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) were significantly different between the intervention groups, strongly indicating allocation imbalance. For example, morning stiffness was 53.75 ± 32.62 units for the MTX group and 21.31 ± 17.88 units for the control group (it was unclear whether the units were measured in minutes).</P>
<P>In the <LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK> study, baseline values for the MTX group were higher than that for the placebo group in four outcomes: morning stiffness VAS (100 mm, where 0 = no stiffness and 100 = severe stiffness: 47 ± 30 versus 30 ± 28; comparison of mean and standard deviation for each group); BASDAI (on a scale from 0 to 10, where 0 = no disease activity and 10 = severe disease activity: 4.7 ± 3 versus 3.5 ± 2); BASFI (on a scale from 0 to 10, where 0 = excellent function and 10 = poor function: 4.7 ± 3 versus 3.5 ± 2); and physician global assessment VAS (100 mm, where 0 = no disease activity and 100 = severe disease activity: 49 ± 30 versus 30 ± 20), although the differences were not statistically significant (P &gt; 0.05).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-01-22 10:02:43 -0500" MODIFIED_BY="Junmin Chen">
<SUBSECTION>
<HEADING LEVEL="3">Major outcomes</HEADING>
<P>The included trials did not report ASAS 40, partial remission, spine x-ray, and MRI results. BASFI was reported in one trial (<LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK>), showing no significant difference between MTX and placebo group (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). </P>
<P>For safety outcomes, higher rates of side effect (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>) and withdrawal for any reason (<LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>) were found in the MTX treated than no MTX treatment group although the differences were not statistically significant. However, serious side effects were rare.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Minor outcomes</HEADING>
<P>The included trials assessed different outcomes including physical function, disease activity, pain, spinal mobility, peripheral joints/entheses, patient global assessment, physician global assessment, morning stiffness, ESR, CRP, response rate, and adverse effects. </P>
<P>We pooled estimates for the outcomes of BASDAI, patient global assessment, physician global assessment and CRP. Since patient global assessment and physician global assessment outcomes were reported using different scales (score 1 to 5 in the <LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK> trial and VAS scale in <LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK>) and the CRP unit used differed (percent change in <LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK> and mg/L in <LINK REF="STD-Roychowdhury-2002" TYPE="STUDY">Roychowdhury 2002</LINK>), we used the SMD values for treatment estimates. None of these outcomes showed a statistically significant difference between the intervention groups (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>).</P>
<P>In the <LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK> trial, the authors looked at changes from baseline values. When they compared the outcomes, they found that only the physician global assessment outcome showed a statistically significant difference between the two groups, with the group receiving MTX favoured over the group that received no MTX. In our analysis, we compared this outcome (end point) and failed to confirm this difference (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>). Rather, we found statistically significant differences between intervention groups in function index, spondylitis index and enthesis index, this time favouring the group that received no MTX over the MTX group. For the function index (0 to 40 scale, where 0 was the best and 40 the worst), the mean difference was 12.65, 95% confidence interval (CI) 0.73 to 24.57 (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). The mean difference for the spondylitis index (0 to10 scale, where the higher the score, the more severe the disease) was 2.25 (95% CI 0.94 to 3.96) (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). The mean difference for the enthesis index (0 to 90 scale, where the higher the score, the more severe the disease) was 2.18 (95% CI 0.01 to 4.35) (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>). Eight patients in the MTX group and none in the placebo group complained of temporary nausea (RR 16.37, 95% CI 0.99 to 269.44) (<LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>).</P>
<P>In <LINK REF="STD-Roychowdhury-2002" TYPE="STUDY">Roychowdhury 2002</LINK>, the change from baseline of Bath ankylosing spondylitis disease activity index (BASDAI) VAS-10 cm, Bath ankylosing spondylitis metrology index (BASMI, score from 0 to 10) and CRP (mg/L) were assessed. No statistically significant differences were found between the MTX group and the placebo group (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>). One patient withdrew because of nausea, rhinorrhoea and headache but it was unclear to which intervention group this patient belonged.</P>
<P>In <LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK> trial, the primary outcome was response, which was defined as improvement greater than or equal to 20% in at least five of following areas with no worsening in any of the scales (&gt;20% worsening compared to baseline):</P>
<UL>
<LI>Severity of morning stiffness VAS;</LI>
<LI>Physical well-being VAS;</LI>
<LI>BASDAI;</LI>
<LI>Bath ankylosing spondylitis functional index (BASFI);</LI>
<LI>Health assessment questionnaire for spondyloarthropathies (HAQ-S);</LI>
<LI>Physician global assessment VAS;</LI>
<LI>Patient global assessment VAS.</LI>
</UL>
<P>According to ITT analysis, a statistically significant difference was found between the intervention groups, favouring the group on MTX over the placebo group (RR = 3.18, 95% CI 1.03 to 9.79; <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and NNT was 3 (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). However, no statistically significant difference was found in all the secondary outcomes, including BASDAI (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), BASFI (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>), spinal pain VAS (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>), disappearance of peripheral arthritis (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>), patient global assessment (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>), and physician global assessment (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>), physical well-being (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>), and health assessment questionnaire for spondyloarthropathies (HAQ-S) (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>). Rates of side effects were similar between the MTX group and placebo group and these included: mild headache, oral ulcerations, upper abdominal pain, nausea, vomiting, non-severe and transitory diarrhoea, transitory liver function abnormalities, loss of hair, and mild infections. Two patients withdrew from the trial, one from the MTX group for lack of compliance and the other from the placebo group because of lack of response (<LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-01-22 10:11:28 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2013-01-22 10:05:29 -0500" MODIFIED_BY="[Empty name]">
<P>In the present review, we identified three RCTs evaluating the benefits and harms of MTX in AS. Two trials (<LINK REF="STD-Roychowdhury-2002" TYPE="STUDY">Roychowdhury 2002</LINK>; <LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK>) compared MTX with placebo and one (<LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK>) compared MTX with no medication. These three trials treated a total of 116 participants. All of the included particpants were considered to have active disease, although the definition of active disease differed between the trials. Among the outcomes reported in these trials, we detected no statistically significant differences favouring MTX over no MTX group from our analyses. The only exception was for the outcome of response rates in the <LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK> trial, which favoured MTX over placebo. This response was judged by 'change from baseline' results of seven outcomes, i.e. morning stiffness VAS, physical well-being VAS, BASDAI, BASFI, HAQ-S, physician global assessment VAS, and patient global assessment VAS. However, none of these seven outcomes showed statistically significant differences between the MTX group and placebo group when endpoint results were compared. Therefore, the benefit of MTX for treatment of AS is questionable. We investigated the <LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK> trial further and found that different baseline values in some of these seven outcomes could partially explain this paradox. The baseline values of the MTX group were higher than those of the placebo group for four outcomes: morning stiffness, BASDAI, BASFI, and physician global assessment, as described in the <LINK TAG="STUDY_QUALITY" TYPE="SECTION">Risk of bias in included studies</LINK> section. We suppose that for patients with more severe disease it was easier for their condition to improve more after treatment when compared withpatients who were in comparatively better health before treatment who experienced less improvement after treatment.</P>
<P>Although there were higher incidences of side effects in the MTX treated than in the no MTX treatment group, MTX was well tolerated and serious side effects were rare.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-01-22 10:05:45 -0500" MODIFIED_BY="[Empty name]">
<P>The study population from the included trials was 116 adult AS patients who fulfilled New York criteria (<LINK REF="REF-Olivieri-2002" TYPE="REFERENCE">Olivieri 2002</LINK>), including obvious sacroiliitis on X-ray. The majority of these patients were at an advanced stage of AS, with mean disease duration ranging from 5.7 to 17 years. Therefore, the evidence was not applicalbe to juvenile patients and those patients with early disease, especially those without radiological sacroiliitis.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-01-22 10:06:10 -0500" MODIFIED_BY="[Empty name]">
<P>The evidence of the present review is not robust enough to draw a conclusion about the benefit of MTX for treatment of AS, because it included only three trials with a total of 116 patients and two of the included trials (<LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK>; <LINK REF="STD-Roychowdhury-2002" TYPE="STUDY">Roychowdhury 2002</LINK>) had obvious methodological drawbacks. Statistically significant results could have been missed because of small sample sizes included in the present review. Dosage of MTX is another consideration: these trials used doses of 7.5 to 15 mg/week whereas the maximum dosage recommended for RA is 25 to 30 mg/week (<LINK REF="REF-ACR-2002" TYPE="REFERENCE">ACR 2002</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-01-22 10:09:22 -0500" MODIFIED_BY="[Empty name]">
<P>We conducted an extensive search of several databases and updated the search during the review process.  We included all trials that met with our inclusion criteria. We did not limit the search to a specific language. When necessary, we attempted to contact the trial authors to clarify any information regarding their trials. Presentation of outcomes was poor in <LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK>: both end point and change from baseline values (percent change or difference scores) were reported. However, it was unclear whether the figures given referred to 'mean ± SD' or 'mean ± standard error (SE)' data, and whether results for outcomes were 'percent change' or 'difference scores'. As a result, caution should be used in interpretation of some outcomes: for example, the figures for morning stiffness were -52.60 ± 0.70 (percent change from baseline, according to the author) for MTX and -35.09 ± 1.01 for the group without MTX, where SD (or SE) was very small. The author of this trial confirmed that this datum was a mistake but was unable to provide the correct value.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-01-22 10:11:28 -0500" MODIFIED_BY="[Empty name]">
<P>The benefit of MTX has been confirmed for treatment of RA (<LINK REF="REF-Suarez_x002d_Almazor-2003" TYPE="REFERENCE">Suarez-Almazor 2003</LINK>; <LINK REF="REF-Katchamart-2010" TYPE="REFERENCE">Katchamart 2010</LINK>). However, regarding use of MTX for treatment of AS, it remains uncertain. There have been several case reports and open studies evaluating MTX for the treatment of AS (<LINK REF="REF-Biasi-2000" TYPE="REFERENCE">Biasi 2000</LINK>; <LINK REF="REF-Clavaguera-1998" TYPE="REFERENCE">Clavaguera 1998</LINK>; <LINK REF="REF-Creemers-1995" TYPE="REFERENCE">Creemers 1995</LINK>; <LINK REF="REF-Handler-1989" TYPE="REFERENCE">Handler 1989</LINK>; <LINK REF="REF-Kirnap-2000" TYPE="REFERENCE">Kirnap 2000</LINK>; <LINK REF="REF-Ostendorf-1998" TYPE="REFERENCE">Ostendorf 1998</LINK>; <LINK REF="REF-Sampaio_x002d_Barros-2000" TYPE="REFERENCE">Sampaio-Barros 2000</LINK>). <LINK REF="REF-Haibel-2007" TYPE="REFERENCE">Haibel 2007</LINK> reported an open-label trial in active AS patients with predominantly axial manifestation, using higher dose of MTX (15 mg subcutaneously for four weeks and 20 mg for 12 weeks). No change from baseline in mean BASDAI was observed at 16 weeks. This result showed that even a higher dose of MTX was ineffective for treatment of AS.</P>
<P>In RA, combination of Infliximab and MTX was shown to cause a synergistic effect (<LINK REF="REF-Maini-1998" TYPE="REFERENCE">Maini 1998</LINK>) and therefore a recommendation has been made for this combination (<LINK REF="REF-Smolen-2010" TYPE="REFERENCE">Smolen 2010</LINK>). For treatment of AS, <LINK REF="REF-Perez_x002d_Guijo-2007" TYPE="REFERENCE">Perez-Guijo 2007</LINK> reported an open label and prospective study of 19 patients with active disease. The results showed that infliximab in combination with MTX increased therapeutic response. Three RCTs (<LINK REF="STD-Breban-2008" TYPE="STUDY">Breban 2008</LINK>; <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK>; <LINK REF="STD-Mulleman-2011" TYPE="STUDY">Mulleman 2011</LINK>) aimed to test whether concomitant use of MTX improved the efficacy of infliximab in people with AS. However, no statistically significant difference was found between MTX and no MTX group in all the assessed outcomes, including ASAS20, ASAS40 and partial remission, indicating that adding MTX to infliximab offers no demonstrable benefit.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-01-22 10:12:09 -0500" MODIFIED_BY="Junmin Chen">
<IMPLICATIONS_PRACTICE MODIFIED="2013-01-22 10:11:34 -0500" MODIFIED_BY="Junmin Chen">
<P>There is not enough evidence to support any benefit of MTX in the treatment of people with AS.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-01-22 10:12:09 -0500" MODIFIED_BY="Junmin Chen">
<P>RCTs of higher methodological quality, i.e. with larger sample sizes and of longer duration, with adequate allocation concealment and triple blinding (patients, care providers, and investigators), are needed to verify the uncertainty about the benefit and toxicity of MTX for the treatment of people with AS.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-01-22 10:12:26 -0500" MODIFIED_BY="Junmin Chen">
<P>We would like to thank the editorial team of the Cochrane Musculoskeletal Group for their helpful comments and Sally Green, Steve McDonald, Janet Piehl, Denise O'Connor, Elmer V Villanueva, and the staff of Australasian Cochrane Centre for their supervision, editorial, and technical support. Also, we would like to thank Chao Liu and Junfang Lin, the original authors for their great contributions to this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-07-21 09:38:10 -0400" MODIFIED_BY="[Empty name]">
<P> There are no known potential conflicts of interest for this review. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-01-22 10:12:52 -0500" MODIFIED_BY="Junmin Chen">
<P>JC registered the title, developed the protocol, searched for relevant studies, selected the studies and assessed their methodological quality, extracted and synthesized the data, and wrote the systematic review.</P>
<P>MMSV (for the update), JFL (for the second version), and CLIO (for the original review) selected studies, assessed their methodological quality, and extracted data from them independently of JC.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-01-22 10:13:06 -0500" MODIFIED_BY="[Empty name]">
<P>In this updated review, we used the Cochrane Collaboration's tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) for assessing risk of bias. We utilised Grade Profiler software and a summary of findings table to present the main results.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-01-22 11:08:02 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-01-22 11:03:33 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-01-22 11:01:17 -0500" MODIFIED_BY="Junmin Chen">
<STUDY DATA_SOURCE="PUB" ID="STD-Altan-2001" MODIFIED="2013-01-22 11:00:48 -0500" MODIFIED_BY="[Empty name]" NAME="Altan 2001" YEAR="">
<REFERENCE MODIFIED="2013-01-22 11:00:48 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altan L, Bingol U, Karakoc Y, Aydiner S, Yurtkuran M, Yurtkuran M</AU>
<TI>Clinical investigation of methotrexate in the treatment of ankylosing spondylitis</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>5</NO>
<PG>255-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonzalez_x002d_Lopez-2004" MODIFIED="2013-01-22 11:01:03 -0500" MODIFIED_BY="[Empty name]" NAME="Gonzalez-Lopez 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-22 11:01:03 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonzalez-Lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Munoz-Valle JF, Gamez-Nava JI</AU>
<TI>Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial</TI>
<SO>The Journal of Rheumatology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>8</NO>
<PG>1568-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roychowdhury-2002" MODIFIED="2013-01-22 11:01:17 -0500" MODIFIED_BY="Junmin Chen" NAME="Roychowdhury 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-18 11:50:49 -0500" MODIFIED_BY="Junmin Chen" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roychowdhury B, Bintley-Bagot S, Bulgen DY, Thompson RN, Tunn EJ, Moots RJ</AU>
<TI>Is methotrexate effective in ankylosing spondylitis?</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>
11
</NO>
<PG>1330-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 11:01:17 -0500" MODIFIED_BY="Junmin Chen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roychowdhury B, Bintley-Bagot S, Hunt J, Tunn EJ</AU>
<TI>Methotrexate in severe ankylosing spondylitis: a randomised placebo controlled, double-blind observer study</TI>
<SO>Rheumatology</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>Suppl 1</NO>
<PG>43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-01-22 11:03:19 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Breban-2008" MODIFIED="2013-01-22 11:01:44 -0500" MODIFIED_BY="Junmin Chen" NAME="Breban 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-22 11:01:33 -0500" MODIFIED_BY="Junmin Chen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, et al</AU>
<TI>Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2008</YR>
<VL>58</VL>
<NO>1</NO>
<PG>88-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 11:01:44 -0500" MODIFIED_BY="Junmin Chen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Breban M, Ravaud P, Claudepierre P, Baron G, Hudry C, Euller-Ziegler L, et al</AU>
<TI>No superiority of infliximab (INF) + methotrexate (MTX) over INF alone in the treatment of ankylosing spondylitits (AS): results of a one-year randomized prospective study</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>Suppl 9</NO>
<PG>S214</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kabasakal-2009" MODIFIED="2013-01-22 11:01:54 -0500" MODIFIED_BY="Junmin Chen" NAME="Kabasakal 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-22 11:01:54 -0500" MODIFIED_BY="Junmin Chen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kabasakal Y, Kitapcioglu G, Yargucu F, Taylan A, Argin M, Gumusdis G</AU>
<TI>Efficacy of SLZ and MTX (alone or combinaiton) on the treatment of sacroiliitis in early AS</TI>
<SO>Rheumatology International</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>12</NO>
<PG>1523-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008" MODIFIED="2013-01-22 11:02:19 -0500" MODIFIED_BY="Junmin Chen" NAME="Li 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-22 11:02:08 -0500" MODIFIED_BY="Junmin Chen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li EK, Griffith JF, Lee VW, Wang YX, Li TK, Lee KK, et al</AU>
<TI>Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Erratum</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2010</YR>
<VL>49</VL>
<NO>7</NO>
<PG>1423</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-22 11:02:19 -0500" MODIFIED_BY="Junmin Chen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li EK, Griffith JF, Lee VW, Wang YX, Li TK, Lee KK, et al</AU>
<TI>Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation</TI>
<SO>Rheumatology (Oxford)</SO>
<YR>2008</YR>
<VL>47</VL>
<NO>9</NO>
<PG>1358-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulleman-2011" MODIFIED="2013-01-22 11:02:40 -0500" MODIFIED_BY="Junmin Chen" NAME="Mulleman 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-22 11:02:40 -0500" MODIFIED_BY="Junmin Chen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulleman D, Lauferon F, Wendling D, Ternant D, Ducourau E, Paintaud G, et al</AU>
<TI>Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study</TI>
<SO>Arthritis Research and Therapy</SO>
<YR>2011</YR>
<VL>13</VL>
<NO>3</NO>
<PG>R82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-25 12:23:05 -0400" MODIFIED_BY="Junmin Chen"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-P_x00e9_rez_x002d_Guijo-2007" MODIFIED="2013-01-22 11:03:09 -0500" MODIFIED_BY="Junmin Chen" NAME="Pérez-Guijo 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-22 11:03:09 -0500" MODIFIED_BY="Junmin Chen" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pérez-Guijo VC, Cravo AR, Castro MdelC, Font P, Muñoz-Gomariz E, Collantes-Estevez E</AU>
<TI>Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis</TI>
<SO>Joint Bone Spine</SO>
<YR>2007</YR>
<VL>74</VL>
<NO>3</NO>
<PG>254-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xie-2003" MODIFIED="2013-01-22 11:03:19 -0500" MODIFIED_BY="[Empty name]" NAME="Xie 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-22 11:03:19 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xie RL, Li XH, Kang XT</AU>
<TI>Methotrexate in conjunction with meloxicam for treating ankylosing spondylitis: a clinical observation of the efficacy and safety</TI>
<SO>Di Yi Jun Yi Da Xue Xue Bao (Academic journal of the First Medical College of PLA)</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>5</NO>
<PG>460-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-01-22 11:03:33 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Haque-1999" MODIFIED="2013-01-22 11:03:33 -0500" MODIFIED_BY="[Empty name]" NAME="Haque 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-01-22 11:03:33 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haque MA, Bari MA, Saha GK, Ali MA, Hoque SA, Abdullah ABM</AU>
<TI>Prospective, nonblind trial of methotrexate on seronegative spondyloarthropathy</TI>
<SO>Journal of Institute of Postgraduate Medicine and Research</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>2</NO>
<PG>56-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-01-22 11:08:02 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-01-22 11:08:02 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-ACR-2002" MODIFIED="2013-01-22 11:03:50 -0500" MODIFIED_BY="[Empty name]" NAME="ACR 2002" TYPE="JOURNAL_ARTICLE">
<AU>American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines</AU>
<TI>Guidelines for the management of rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>2</NO>
<PG>328-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Akkoc-2005" MODIFIED="2013-01-22 11:03:58 -0500" MODIFIED_BY="Junmin Chen" NAME="Akkoc 2005" TYPE="JOURNAL_ARTICLE">
<AU>Akkoc N, Khan MA</AU>
<TI>Overestimation of the prevalence of ankylosing spondylitis in the Berlin study: comment on the article by Braun et al</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>12</NO>
<PG>4048-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Annelies-2006" MODIFIED="2013-01-22 11:04:08 -0500" MODIFIED_BY="Junmin Chen" NAME="Annelies 2006" TYPE="JOURNAL_ARTICLE">
<AU>Boonen A, van der Linden SM</AU>
<TI>The burden of ankylosing spondylitis</TI>
<SO>The Journal of Rheumatology. Supplement</SO>
<YR>2006</YR>
<VL>78</VL>
<PG>4-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Biasi-2000" MODIFIED="2013-01-22 11:04:19 -0500" MODIFIED_BY="[Empty name]" NAME="Biasi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM</AU>
<TI>Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study</TI>
<SO>Clinical Rheumatology</SO>
<YR>2000</YR>
<VL>19</VL>
<NO>2</NO>
<PG>114-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-2005" MODIFIED="2012-09-17 11:31:43 -0400" MODIFIED_BY="Junmin Chen" NAME="Chen 2005" TYPE="COCHRANE_REVIEW">
<AU>Chen J, Liu C</AU>
<TI>Sulfasalazine for ankylosing spondylitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<PG>Art. No.: CD004800</PG>
<IDENTIFIERS MODIFIED="2012-05-24 11:42:21 -0400" MODIFIED_BY="Junmin Chen">
<IDENTIFIER MODIFIED="2012-05-24 11:42:21 -0400" MODIFIED_BY="Junmin Chen" TYPE="DOI" VALUE="10.1002/14651858.CD004800.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Clavaguera-1998" MODIFIED="2013-01-22 11:04:38 -0500" MODIFIED_BY="[Empty name]" NAME="Clavaguera 1998" TYPE="JOURNAL_ARTICLE">
<AU>Clavaguera MT, Juanola X, Narvaez FJ</AU>
<TI>Methotrexate in the treatment of ankylosing spondylitis</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1998</YR>
<VL>37</VL>
<NO>Suppl 1</NO>
<PG>45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Creemers-1995" MODIFIED="2013-01-18 12:27:59 -0500" MODIFIED_BY="[Empty name]" NAME="Creemers 1995" TYPE="JOURNAL_ARTICLE">
<AU>Creemers MC, Franssen MJ, van de Putte LB, Gribnau FW, van Riel PL</AU>
<TI>Methotrexate in severe ankylosing spondylitis: an open study</TI>
<SO>Journal of Rheumatology</SO>
<YR>1995</YR>
<VL>22</VL>
<NO>6</NO>
<PG>1104-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haibel-2007" MODIFIED="2013-01-22 11:04:51 -0500" MODIFIED_BY="[Empty name]" NAME="Haibel 2007" TYPE="JOURNAL_ARTICLE">
<AU>Haibel H, Brandt HC, Song IH, Brandt A, Listing J, Rudwaleit M, et al</AU>
<TI>No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2007</YR>
<VL>66</VL>
<NO>3</NO>
<PG>419-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Handler-1989" MODIFIED="2013-01-22 11:05:01 -0500" MODIFIED_BY="[Empty name]" NAME="Handler 1989" TYPE="JOURNAL_ARTICLE">
<AU>Handler RP</AU>
<TI>Favourable results using methotrexate in the treatment of patients with ankylosing spondylitis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1989</YR>
<VL>32</VL>
<NO>2</NO>
<PG>234</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2013-01-22 11:05:37 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins J, Altman DG</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2 (updated September 2009. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Katchamart-2010" MODIFIED="2012-12-06 05:53:52 -0500" MODIFIED_BY="Junmin Chen" NAME="Katchamart 2010" TYPE="COCHRANE_REVIEW">
<AU>Katchamart W, Trudeau J, Phumethum V, Bombardier C</AU>
<TI>Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-05-24 11:54:56 -0400" MODIFIED_BY="Junmin Chen">
<IDENTIFIER MODIFIED="2012-05-24 11:54:56 -0400" MODIFIED_BY="Junmin Chen" TYPE="DOI" VALUE="10.1002/14651858.CD008495"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kirnap-2000" MODIFIED="2013-01-22 11:05:53 -0500" MODIFIED_BY="[Empty name]" NAME="Kirnap 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kirnap M, Demir H, Sigan YT, Koc H, Ozsoy O</AU>
<TI>Efficacy and side effects of low dose methotrexate treatment in the patients with ankylosing spondylitis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>Suppl 59</NO>
<PG>57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maini-1998" MODIFIED="2013-01-22 11:06:00 -0500" MODIFIED_BY="Junmin Chen" NAME="Maini 1998" TYPE="JOURNAL_ARTICLE">
<AU>Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, et al</AU>
<TI>Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>9</NO>
<PG>1552-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLeod-2007" MODIFIED="2013-01-18 12:43:41 -0500" MODIFIED_BY="[Empty name]" NAME="McLeod 2007" TYPE="JOURNAL_ARTICLE">
<AU>McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al</AU>
<TI>Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation</TI>
<SO>Health Technology Assessment</SO>
<YR>2007</YR>
<VL>11</VL>
<NO>28</NO>
<PG>1-158</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olivieri-2002" MODIFIED="2013-01-22 11:06:21 -0500" MODIFIED_BY="[Empty name]" NAME="Olivieri 2002" TYPE="JOURNAL_ARTICLE">
<AU>Olivieri I, van Tubergen A, Salvarani C, van der Linden S</AU>
<TI>Seronegative spondyloarthritides</TI>
<SO>Best Practice and Research. Clinical Rheumatology</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>5</NO>
<PG>723-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ostendorf-1998" MODIFIED="2013-01-22 11:06:36 -0500" MODIFIED_BY="[Empty name]" NAME="Ostendorf 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ostendorf B, Specker C, Schneider M</AU>
<TI>Methotrexate lacks efficacy in the treatment of severe ankylosing spondylitis compared with rheumatoid and psoriatic arthritis</TI>
<SO>Journal of Clinical Rheumatology</SO>
<YR>1998</YR>
<VL>4</VL>
<NO>3</NO>
<PG>129-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perez_x002d_Guijo-2007" MODIFIED="2013-01-22 11:06:47 -0500" MODIFIED_BY="Junmin Chen" NAME="Perez-Guijo 2007" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Guijo VC, Cravo AR, Castro Mdel C, Font P, Munoz-Gomariz E, Collantes-Estevez E</AU>
<TI>Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis.</TI>
<SO>Joint Bone Spine</SO>
<YR>2007</YR>
<VL>74</VL>
<NO>3</NO>
<PG>254-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Review-Manager-_x0028_RevMan_x0029_" MODIFIED="2013-01-22 11:06:56 -0500" MODIFIED_BY="[Empty name]" NAME="Review Manager (RevMan)" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sampaio_x002d_Barros-2000" MODIFIED="2013-01-18 12:48:44 -0500" MODIFIED_BY="[Empty name]" NAME="Sampaio-Barros 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM</AU>
<TI>Methotrexate in the treatment of ankylosing spondylitis</TI>
<SO>Scandinavian Journal of Rheumatology</SO>
<YR>2000</YR>
<VL>29</VL>
<NO>
3
</NO>
<PG>160-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sieper-2009" MODIFIED="2013-01-22 11:07:20 -0500" MODIFIED_BY="Junmin Chen" NAME="Sieper 2009" TYPE="JOURNAL_ARTICLE">
<AU>Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al</AU>
<TI>The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis</TI>
<SO>Annal of the Rheumatic Diseases</SO>
<YR>2009</YR>
<VL>68</VL>
<NO>Suppl 2</NO>
<PG>ii1-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smolen-2010" MODIFIED="2013-01-22 11:07:32 -0500" MODIFIED_BY="Junmin Chen" NAME="Smolen 2010" TYPE="JOURNAL_ARTICLE">
<AU>Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al</AU>
<TI>EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2010</YR>
<VL>69</VL>
<NO>6</NO>
<PG>964-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suarez_x002d_Almazor-2003" MODIFIED="2008-11-05 14:53:10 -0500" MODIFIED_BY="[Empty name]" NAME="Suarez-Almazor 2003" TYPE="COCHRANE_REVIEW">
<AU>Suarez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P</AU>
<TI>Methotrexate for treating rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-05 14:53:10 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-05 14:53:10 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000957"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-der-Heijde-1999" MODIFIED="2013-01-22 11:07:42 -0500" MODIFIED_BY="[Empty name]" NAME="van der Heijde 1999" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, van der Linden S, Bellamy N, Calin A, Dougados M, Khan MA</AU>
<TI>Which domains should be included in a core set for endpoints in ankylosing spondylitis? Introduction to the ankylosing spondylitis module of OMERACT IV</TI>
<SO>The Journal of Rheumatology</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>4</NO>
<PG>945-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Heijde-2002" MODIFIED="2013-01-22 11:07:50 -0500" MODIFIED_BY="[Empty name]" NAME="van der Heijde 2002" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Braun J, McGonagle D, Siegel J</AU>
<TI>Treatment trials in ankylosing spondylitis: current and future considerations</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61(Suppl 3)</VL>
<PG>iii24-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Heijde-2005" MODIFIED="2013-01-22 11:08:02 -0500" MODIFIED_BY="Junmin Chen" NAME="van der Heijde 2005" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde D, Dougados M, Davis J, Weisman MH, Maksymowych W, Braun J, et al</AU>
<TI>Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>2</NO>
<PG>386-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zochling-2005" MODIFIED="2012-09-17 11:32:17 -0400" MODIFIED_BY="Junmin Chen" NAME="Zochling 2005" TYPE="COCHRANE_REVIEW">
<AU>Zochling J, Maxwell L, Beardmore J, Boonen A</AU>
<TI>TNF-alpha inhibitors for ankylosing spondylitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<PG>Art. No.: CD005468</PG>
<IDENTIFIERS MODIFIED="2012-05-24 11:57:55 -0400" MODIFIED_BY="Junmin Chen">
<IDENTIFIER MODIFIED="2012-05-24 11:57:55 -0400" MODIFIED_BY="Junmin Chen" TYPE="DOI" VALUE="10.1002/14651858.CD005468"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-05-24 12:00:51 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Chen-2004" MODIFIED="2011-11-09 13:39:33 -0500" MODIFIED_BY="[Empty name]" NAME="Chen 2004" TYPE="COCHRANE_REVIEW">
<AU>Chen J, Liu C</AU>
<TI>Methotrexate for ankylosing spondylitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons</PB>
<IDENTIFIERS MODIFIED="2011-11-09 13:39:33 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-09 13:39:33 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004524.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chen-2006" MODIFIED="2012-05-24 12:00:51 -0400" MODIFIED_BY="Junmin Chen" NAME="Chen 2006" TYPE="COCHRANE_REVIEW">
<AU>Chen J, Liu C, Lin J</AU>
<TI>Methotrexate for ankylosing spondylitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-05-24 12:00:51 -0400" MODIFIED_BY="Junmin Chen">
<IDENTIFIER MODIFIED="2012-05-24 12:00:51 -0400" MODIFIED_BY="Junmin Chen" TYPE="DOI" VALUE="10.1002/14651858.CD004524.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-01-22 10:14:13 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-01-22 10:14:08 -0500" MODIFIED_BY="[Empty name]" SORT_BY="YEAR" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-01-22 10:13:31 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Altan-2001">
<CHAR_METHODS MODIFIED="2013-01-22 10:13:14 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized allocation: randomization method not given.<BR/>Outcome assessment blinded.<BR/>Treatment allocation possibly open to patients and care providers.<BR/>Parallel groups.<BR/>Duration: 12 months.<BR/>Sample size at entry: 51.<BR/>MTX and naproxen group: 26.<BR/>Naproxen group: 25.<BR/>Personal communication with the trial report author confirmed that all participants completed the trial, and results include all the participants.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-22 10:13:16 -0500" MODIFIED_BY="[Empty name]">
<P>Patients with AS fulfilling New York criteria.<BR/>Other inclusion criteria:<BR/>morning stiffness &gt; 15 min; sleep disturbance caused by pain; limitation of daily functional activity; CRP &gt; 0.5 mg/dl.<BR/>Exclusion criteria:<BR/>total ankylosis involving the whole spine; failure of hepatic and renal tests; severe anaemia, leucopenia or thrombocytopenia.<BR/>Age: 46.78 years ± 11.76 (mean ± SD).<BR/>M:F ratio: 76%: 24%.<BR/>Mean disease duration: 9.52 (4 to 30) years.<BR/>HLA B27 positive: 88.2%.<BR/>With peripheral arthritis: 12%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-01-22 10:13:19 -0500" MODIFIED_BY="[Empty name]">
<P>MTX + naproxen group: MTX orally, 7.5 mg/week, plus naproxen 1000 mg/day.<BR/>Naproxen group: naproxen 1000 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-22 10:13:28 -0500" MODIFIED_BY="[Empty name]">
<P>1. Morning stiffness (units of scale not specified, we assumed the scale was in minutes).<BR/>2. Pain in the day (VAS 0 to 10 cm, where 0 = no pain and 10 = severe pain).<BR/>3. Pain in the night (VAS 0 to 10 cm, where 0 = no pain and 10 = severe pain).<BR/>4. Patient global assessment (scale of 1 to 5, where 1 = no disease activity and 5 = severe disease activity).<BR/>5. Physician global assessment (scale of 1 to 5, where 1 = no disease activity and 5 = severe disease activity).<BR/>6. Enthesis index (0 to 90, where the more severe the disease, the higher the score).<BR/>7. Function index (score 0 to 40, where 0 = the best and 40 = the worst).<BR/>8. Spondylitis index (score 0 to 10, where the more severe the disease, the higher the score).<BR/>9. ESR (percent change from baseline, according to information from author).<BR/>10. CRP (change from baseline, according to information from author).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-22 10:13:31 -0500" MODIFIED_BY="[Empty name]">
<P>Outcomes were poorly presented, for example:<BR/>Morning stiffness was -35.09 ± 1.01 (naproxen alone) and -52.60 ± 0.70 (naproxen plus MTX), respectively. The unit was unknown and likely to be minute. We are not sure whether this figure was mean ± SD or mean ± SE. Nor are we sure whether this figure was score or percent change from baseline. According to author's correspondence, data were presented as percent change from baseline. After discussion, we entered end point mean ± SD (we assumed as SD) values.<BR/>Some baseline parameters were significantly different between intervention groups (summarised in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).<BR/>Our attempts to contact the authors to clarify the uncertainties have been unsuccessful so far.</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-22 10:13:44 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roychowdhury-2002">
<CHAR_METHODS MODIFIED="2013-01-22 10:13:34 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized allocation: randomization and concealment methods not specified.<BR/>Outcome assessment blinded.<BR/>Patients and care providers blinded.<BR/>Parallel groups.<BR/>Duration: 24 weeks.<BR/>Sample size at entry: 30.<BR/>MTX group: 12 completed;<BR/>Placebo group: 16 completed.<BR/>Two participants withdrew, but it was unclear to which intervention group(s) they belonged.<BR/>Outcomes of each patient were provided.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-22 10:13:37 -0500" MODIFIED_BY="[Empty name]">
<P>Patients with AS fulfilling modified New York criteria and active disease defined as at least two of the following symptoms despite treatment with NSAIDs and/or other DMARDs:<BR/>morning stiffness &gt; 30 min; sleep disturbance due to pain and stiffness; peripheral arthritis; ESR &gt; 30 mm/h or CRP &gt; 20 mg/L; spinal pain; pain in both buttocks during the day or night.<BR/>Sulphasalazine or other DMARDs discontinued at least four weeks before study entry.<BR/>Exclusion criteria:<BR/>serious systemic disease, malignancies, impaired organ function or serious infections; pregnancy and breast feeding; mental disorders; alcohol or drug abuse; history of intestinal disease.<BR/>Age: 44 ± 10 years (mean ± SD).<BR/>M:F ratio: 87%: 13%.<BR/>Mean disease duration: 17 (3 to 26) years.<BR/>With peripheral arthritis: 30%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>MTX group: MTX, orally, 10 mg/week.<BR/>Placebo group: placebo orally, 10 mg/week.</P>
<P>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-22 10:13:38 -0500" MODIFIED_BY="[Empty name]">
<P>1. Bath ankylosing spondylitis disease activity index (BASDAI) (change from baseline) (VAS-10cm, where 0 = no disease activity and 10 = severe disease activity).<BR/>2. Bath ankylosing spondylitis metrology (BASMI) (change from baseline) (score from 0 to 10, where 0 = severely limited spinal mobility and 10 = overall normal).<BR/>3. CRP (change from baseline) (mg/L).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-22 10:13:44 -0500" MODIFIED_BY="[Empty name]">
<P>30 patients entered the trial and 28 completed.<BR/>It is not known to which intervention group the two drop-outs belonged.<BR/>Our attempts to contact the authors have been unsuccessful to date.<BR/>Each patient's data were given, from which we calculated the summary values.</P>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-01-22 10:14:07 -0500" MODIFIED_BY="Junmin Chen" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004">
<CHAR_METHODS MODIFIED="2013-01-22 10:13:50 -0500" MODIFIED_BY="[Empty name]">
<P>Randomized allocation: computer generated randomization numbers.<BR/>Patients, care-providers and outcome investigators blinded.<BR/>Parallel groups.<BR/>Duration: 24 weeks.<BR/>Sample size at entry: 35<BR/>MTX - 17<BR/>Placebo - 18<BR/>Withdrawals and drop-outs clearly specified. Outcomes analysis: ITT.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-01-22 10:13:56 -0500" MODIFIED_BY="[Empty name]">
<P>Patients with AS fulfilling New York criteria.<BR/>Other inclusion criteria:<BR/>minimum duration since diagnosis one year; having active disease at the time of the baseline evaluation, defined by the combination of three conditions: (1) physician assessment VAS at least 30 mm (0 to 100), (2) presence of inflammatory back pain (stiffness and pain worsening with rest and improving with exercise), (3) morning stiffness lasting 45 mins and/or peripheral arthritis; aged 18 years or more; stable dose of anti-inflammatory drugs; DMARDs ceased eight weeks before entry.<BR/>Exclusion criteria:<BR/>previous MTX treatment; history of hepatitis, pneumonitis; anaemia (Hb lower than 11 g/L); active infection, alcohol or drug abuse, mental or psychiatric disorders; those requiring corticosteroid or immunosuppressive treatment(s).<BR/>Age: 32 years ± 10 (MTX group), 38 years ± 10 (placebo group) (mean ± SD).<BR/>M:F ratio: 69%: 31%.<BR/>Mean disease duration since first symptoms: 9.5 ± 8 years (MTX group), 5.7 ± 5 years (placebo group).<BR/>With peripheral arthritis: 60%.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>MTX group: MTX 7.5 mg/week orally.<BR/>Placebo group: placebo orally, </P>
<P>
<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-01-22 10:14:00 -0500" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: response in the composite index (*see Notes section for this trial for details).<BR/>Secondary outcomes:<BR/>1. Morning stiffness (VAS 100 mm, 0 = no stiffness, 100 = severe).<BR/>2. Physical well-being (VAS 100 mm, 0 = feeling very well, 100 = feeling very bad).<BR/>3. Bath ankylosing spondylitis disease activity index (BASDAI) (from 0 to 10, 0 = no disease activity and 10 = severe disease activity).<BR/>4. Bath ankylosing spondylitis functional index (BASFI) (from 0 to 10, 0 = excellent, 10 = poor function).<BR/>5. Physician global assessment (VAS 100 mm, 0 = no disease activity and 100 = severe disease activity).<BR/>6. Patient global assessment (VAS 100 mm, 0 = no disease activity and 100 = severe disease activity).<BR/>7. Health assessment questionnaire for spondyloarthropathies (HAQ-S) (from 0 to 3, 0 = no difficulty and 3 = unable to do).<BR/>8. Spinal pain (VAS 10 cm, 0 = no pain, 10 = severe).<BR/>9. Disappearance of peripheral arthritis (event).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-01-22 10:14:07 -0500" MODIFIED_BY="Junmin Chen">
<P>* Composite index defined by improvement of 20% in at least 5 of following:<BR/>1. Severity of morning stiffness VAS 100 mm;<BR/>2. Physical well-being VAS 100 mm;<BR/>3. BASDAI;<BR/>4. BASFI;<BR/>5. HAQ-S;<BR/>6. Physician global assessment VAS 100 mm;<BR/>7. Patient global assessment VAS 100 mm.<BR/>as well as no worsening in any of the scales (defined as &gt;20% worsening compared to baseline).</P>
<P>8. Disappearance of peripheral arthritis</P>
<P>9. Spinal pain (from 0 to 10)<BR/>All outcomes reported as mean ± SD of endpoint value except BASFI. Mean change from baseline ± SD reported for BASFI.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-01-22 10:14:13 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-05-26 04:12:02 -0400" MODIFIED_BY="Junmin Chen" STUDY_ID="STD-Breban-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-26 04:12:02 -0400" MODIFIED_BY="Junmin Chen">
<P>There is another separate Cochrane review addressing biologics in AS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-22 10:14:11 -0500" MODIFIED_BY="Junmin Chen" STUDY_ID="STD-Kabasakal-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-22 10:14:11 -0500" MODIFIED_BY="Junmin Chen">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-05-26 04:12:23 -0400" MODIFIED_BY="Junmin Chen" STUDY_ID="STD-Li-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-05-26 04:12:23 -0400" MODIFIED_BY="Junmin Chen">
<P>There is another separate Cochrane review addressing biologics in AS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-25 12:23:43 -0400" MODIFIED_BY="Junmin Chen" STUDY_ID="STD-Mulleman-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-25 12:23:43 -0400" MODIFIED_BY="Junmin Chen">
<P>There is another separate Cochrane review addressing biologics in AS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-01-22 10:14:13 -0500" MODIFIED_BY="Junmin Chen" STUDY_ID="STD-P_x00e9_rez_x002d_Guijo-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-01-22 10:14:13 -0500" MODIFIED_BY="Junmin Chen">
<P>Not a RCT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Xie-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial compared the effects of different dosage of MTX and did not include the comparison specified in the inclusion criteria.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2011-03-24 11:33:57 -0400" MODIFIED_BY="Junmin Chen" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2011-03-24 11:33:57 -0400" MODIFIED_BY="Junmin Chen" STUDY_ID="STD-Haque-1999">
<CHAR_METHODS MODIFIED="2011-03-24 11:21:13 -0400" MODIFIED_BY="Junmin Chen">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-24 11:26:26 -0400" MODIFIED_BY="Junmin Chen">
<P>Patients with seronegative spondyloarthropathies. Data of AS patients were not available in the article abstract.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-24 11:23:01 -0400" MODIFIED_BY="Junmin Chen">
<P>Methotrexate. Comparison is unknown.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-24 11:23:55 -0400" MODIFIED_BY="Junmin Chen">
<P>Therapeutic response.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-24 11:33:57 -0400" MODIFIED_BY="Junmin Chen">
<P>This study could not be reviewed because of lack of full text.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-01-22 10:14:08 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-11-20 11:55:11 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-20 11:55:11 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altan-2001">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgment of low risk or high risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-14 23:45:28 -0400" MODIFIED_BY="Junmin Chen" RESULT="YES" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004">
<DESCRIPTION>
<P>Computer generated random list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-20 11:54:44 -0500" MODIFIED_BY="Junmin Chen" RESULT="UNKNOWN" STUDY_ID="STD-Roychowdhury-2002">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of low risk or high risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-11-20 11:55:14 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-20 11:55:14 -0500" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altan-2001">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgment of low risk or high risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-14 23:46:16 -0400" MODIFIED_BY="Junmin Chen" RESULT="YES" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004">
<DESCRIPTION>
<P>Sequentially numbered drug containers of identical appearance.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-20 11:54:53 -0500" MODIFIED_BY="Junmin Chen" RESULT="UNKNOWN" STUDY_ID="STD-Roychowdhury-2002">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of low risk or high risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-05-25 09:19:32 -0400" MODIFIED_BY="Junmin Chen" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-14 22:57:39 -0400" MODIFIED_BY="Junmin Chen" RESULT="NO" STUDY_ID="STD-Altan-2001">
<DESCRIPTION>
<P>Only outcome assessment was reported to be blind. Because they did not use placebo, blinding of personnel and participants was impossible.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-14 23:46:44 -0400" MODIFIED_BY="Junmin Chen" RESULT="YES" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004">
<DESCRIPTION>
<P>The patients and researchers involved in administration of the interventions, clinical evaluations, and statistical analyses were blinded to the treatment assignment for the duration of the trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-14 23:24:55 -0400" MODIFIED_BY="Junmin Chen" RESULT="YES" STUDY_ID="STD-Roychowdhury-2002">
<DESCRIPTION>
<P>Reported as double blind, placebo-controlled.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-01-22 10:13:46 -0500" MODIFIED_BY="Junmin Chen" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-14 23:16:19 -0400" MODIFIED_BY="Junmin Chen" RESULT="YES" STUDY_ID="STD-Altan-2001">
<DESCRIPTION>
<P>No missing outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-14 23:50:33 -0400" MODIFIED_BY="Junmin Chen" RESULT="YES" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004">
<DESCRIPTION>
<P>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-01-22 10:13:46 -0500" MODIFIED_BY="Junmin Chen" RESULT="YES" STUDY_ID="STD-Roychowdhury-2002">
<DESCRIPTION>
<P>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-01-22 10:14:08 -0500" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-14 23:41:20 -0400" MODIFIED_BY="Junmin Chen" RESULT="YES" STUDY_ID="STD-Altan-2001">
<DESCRIPTION>
<P>The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-22 10:14:08 -0500" MODIFIED_BY="Junmin Chen" RESULT="YES" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004">
<DESCRIPTION>
<P>The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-22 10:13:47 -0500" MODIFIED_BY="Junmin Chen" RESULT="YES" STUDY_ID="STD-Roychowdhury-2002">
<DESCRIPTION>
<P>The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-01-14 11:48:38 -0500" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-06 12:16:25 -0400" MODIFIED_BY="Junmin Chen" RESULT="NO" STUDY_ID="STD-Altan-2001">
<DESCRIPTION>
<P>Some baseline parameters were significantly different between intervention groups. Furthermore, presentation of outcomes was poor. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-01-14 11:48:38 -0500" MODIFIED_BY="Junmin Chen" RESULT="NO" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004">
<DESCRIPTION>
<P>Some baseline parameters were significantly different between intervention groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-14 23:53:28 -0400" MODIFIED_BY="Junmin Chen" RESULT="YES" STUDY_ID="STD-Roychowdhury-2002">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-01-22 12:09:01 -0500" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-01-22 12:09:01 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-01-22 10:15:27 -0500" MODIFIED_BY="[Empty name]">MTX treated compared to no MTX treated for AS</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>MTX treated compared to no MTX treated for AS </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> Patients with AS<BR/>
<B>Settings: </B>Inpatient clinic in Turkey (<LINK REF="STD-Altan-2001" TYPE="STUDY">Altan 2001</LINK>), outpatient rheumatology clinic in Guadalajara, Mexico (<LINK REF="STD-Gonzalez_x002d_Lopez-2004" TYPE="STUDY">Gonzalez-Lopez 2004</LINK>), and United Kingdom (<LINK REF="STD-Roychowdhury-2002" TYPE="STUDY">Roychowdhury 2002</LINK>)<BR/>
<B>Intervention:</B> MTX<BR/>
<B>Comparison: </B>No MTX</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>No MTX</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>MTX</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>ASAS 40 </B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Partial remission</B>
</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>BASFI (score from 0 to 10, 0=excellent, 10=poor function) </B>
<BR/>
<BR/>Follow-up: 24 weeks</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>The mean change </P>
<P>in BASFI score in the control group was<BR/>
<B>0.4 </B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>The mean change </P>
<P>in BASFI score in the intervention group was<BR/>
<B>0.9 lower</B>
</P>
<P>(0.43 lower to 2.23 higher)<BR/>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>35<BR/>(1 study)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
</P>
<P/>
<P>
<B>low</B>
<SUP>1,2</SUP>
</P>
<P/>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>MD = 0.9 (-0.43 to 2.23)</P>
<P/>
<P>Relative improvement 8.57%<BR/>(95% CI 29.42 to 46.57)</P>
<P/>
<P>Absolute improvement</P>
<P>3% (95% CI 10.3% to 16.3%)</P>
<P/>
<P>Not statistically significant</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>X-Ray of the spine</B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>MRI </B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P/>
<P>
<B>Serious adverse event</B>
</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Not reported</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Withdrawal for any reason</B>
</P>
<P/>
<P>Follow-up: 24 weeks</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>
<B>56 per 1000</B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>
<B>59 per 1000</B>
<BR/>(4 to 868)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>
<B>RR 1.06 </B>
<BR/>(0.07 to 15.62)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>35<BR/>(1 study)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
</P>
<P/>
<P>
<B>low</B>
<SUP>1,2</SUP>
</P>
<P/>
<P/>
<P/>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>Relative percent change 6 %<BR/>(95% CI 93% to 1462%)</P>
<P/>
<P>Absolute risk difference 0%<BR/>(95% CI 15% to 16%)</P>
<P/>
<P>Not statistically significant</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Baseline imbalance.</P>
<P>
<SUP>2</SUP> Few patients and few events.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-01-22 10:22:26 -0500" MODIFIED_BY="Junmin Chen">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2013-01-22 10:22:10 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-01-22 10:21:56 -0500" MODIFIED_BY="[Empty name]">Comparison of baseline parameters between no MTX treatment and MTX treated group in Altan 2001</TITLE>
<TABLE COLS="9" ROWS="3">
<TR>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Intervention</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Function index</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Pain in the day</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Pain in the night</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Spondylitis index</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Enthesis index</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Patient assessment</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Physician assessment</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>Morning stiffness</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MTX</P>
</TD>
<TD>
<P>29.12 ± 25.18</P>
</TD>
<TD>
<P>3.93 ± 2.06</P>
</TD>
<TD>
<P>5.28 ± -2.38</P>
</TD>
<TD>
<P>3.31 ± 3.21</P>
</TD>
<TD>
<P>7.21 ± 7.46</P>
</TD>
<TD>
<P>2.65 ± 1.00</P>
</TD>
<TD>
<P>3.09 ± 0.89</P>
</TD>
<TD>
<P>53.75 ± 32.62</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>No MTX</P>
</TD>
<TD>
<P>20.89 ± 18.10</P>
</TD>
<TD>
<P>4.00 ± 2.80</P>
</TD>
<TD>
<P>4.10 ± 3.07</P>
</TD>
<TD>
<P>1.00 ± 1.91</P>
</TD>
<TD>
<P>3.78 ± 5.02</P>
</TD>
<TD>
<P>2.73 ± 0.99</P>
</TD>
<TD>
<P>2.21 ± 0.97</P>
</TD>
<TD>
<P>21.31 ± 17.88</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2013-01-22 10:22:26 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Clinical relevance table - dichotomous</TITLE>
<TABLE COLS="8" ROWS="3">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH ALIGN="CENTER">
<P># Patients (# Trials)</P>
</TH>
<TH ALIGN="CENTER">
<P>Control event rate</P>
</TH>
<TH ALIGN="CENTER">
<P>Absolute RD</P>
</TH>
<TH ALIGN="CENTER">
<P>Relative % change</P>
</TH>
<TH ALIGN="CENTER">
<P>NNT</P>
</TH>
<TH ALIGN="CENTER">
<P>Statistical significance</P>
</TH>
<TH ALIGN="CENTER">
<P>Quality of evidence</P>
</TH>
</TR>
<TR>
<TD>
<P>Response to composite index at 24 weeks<BR/>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>35 (1)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>16.7% (3/18)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>36%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>218% (I)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>statistically significant</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Response to composite index: defined by improvement &#8805; 20% at</P>
<P>least 5 of following and no worsening in any of the scales (&gt;20% worsening compared to baseline): severity of morning stiffness; 
</P>
<P>physical well-being; BASDAI; BASFI; HAQ-S; physician global assessment; and patient global assessment.<BR/>MTX = methotrexate; RR = relative risk, RD = risk difference, NNT = number needed to treat<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>I = improvement</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Baseline imbalance.</P>
<P>
<SUP>2</SUP> Few patients and few events.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-01-22 11:00:15 -0500" MODIFIED_BY="Junmin Chen">
<COMPARISON ID="CMP-001" MODIFIED="2013-01-22 11:00:15 -0500" MODIFIED_BY="Junmin Chen" NO="1">
<NAME>MTX versus No MTX</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-12-14 11:15:34 -0500" MODIFIED_BY="Junmin Chen" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="20.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="17" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Response in the composite index</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.794252999862742" CI_START="1.0301924402060352" EFFECT_SIZE="3.176470588235294" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9909713182879951" LOG_CI_START="0.012918358601394167" LOG_EFFECT_SIZE="0.5019448384446945" MODIFIED="2012-12-14 10:24:36 -0500" MODIFIED_BY="[Empty name]" ORDER="26107" O_E="0.0" SE="0.5745131499601416" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004" TOTAL_1="17" TOTAL_2="18" VAR="0.3300653594771241" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="4.316450259566901" CI_END="3.144725770335415" CI_START="-1.2210254310816269" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9618501696268938" ESTIMABLE="YES" I2="76.83281539539074" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="2" P_CHI2="0.03774577392786782" P_Q="1.0" P_Z="0.38779248744551675" Q="0.0" RANDOM="YES" SCALE="5.89" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="1.910409538398692" TOTALS="YES" TOTAL_1="29" TOTAL_2="34" UNITS="" WEIGHT="100.0" Z="0.863627634291462">
<NAME>BASDAI (VAS-10 cm, 0=no disease activity, 10=severe disease activity) (end point value)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.2257187406846675" CI_START="-1.4257187406846676" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="3.5" MODIFIED="2012-05-25 09:47:30 -0400" MODIFIED_BY="Junmin Chen" ORDER="57" SD_1="2.0" SD_2="2.0" SE="0.6763995415945231" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="52.3834004651617"/>
<CONT_DATA CI_END="3.7634445950774005" CI_START="0.4965554049225991" EFFECT_SIZE="2.13" ESTIMABLE="YES" MEAN_1="6.84" MEAN_2="4.71" MODIFIED="2012-05-25 09:48:58 -0400" MODIFIED_BY="Junmin Chen" ORDER="59" SD_1="2.29" SD_2="2.03" SE="0.8334054135493322" STUDY_ID="STD-Roychowdhury-2002" TOTAL_1="12" TOTAL_2="16" WEIGHT="47.61659953483829"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.2257187406846675" CI_START="-0.42571874068466753" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2013-01-14 12:09:36 -0500" MODIFIED_BY="Junmin Chen" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.18332904885053003" Q="0.0" RANDOM="YES" SCALE="4.51" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="1.3305745268223692">
<NAME>BASFI (score 0-10, 0=excellent, 10=poor function) (change from baseline)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.2257187406846675" CI_START="-0.42571874068466753" EFFECT_SIZE="0.9" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="0.4" MODIFIED="2013-01-14 11:31:35 -0500" MODIFIED_BY="Junmin Chen" ORDER="60" SD_1="2.0" SD_2="2.0" SE="0.6763995415945231" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="26" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Function index (score 0-40, 0=the best, 40=the worst) (end point value)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="24.56896688957123" CI_START="0.731033110428772" EFFECT_SIZE="12.65" ESTIMABLE="YES" MEAN_1="27.59" MEAN_2="14.94" ORDER="1" SD_1="27.03" SD_2="14.9" SE="6.081217299698626" STUDY_ID="STD-Altan-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="26" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pain in the night (VAS-10 cm, 0=no pain, 10=severe pain) (end point value)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.0195014455215095" CI_START="-0.8995014455215102" EFFECT_SIZE="0.5599999999999996" ESTIMABLE="YES" MEAN_1="3.03" MEAN_2="2.47" ORDER="1" SD_1="2.92" SD_2="2.38" SE="0.744657277906059" STUDY_ID="STD-Altan-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.221997948534624" CI_START="-0.4419979485346244" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.8899999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.19033539833395172" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="1.3095875621728141">
<NAME>Pain in the day (VAS-10 cm, 0=no pain, 10=severe pain) (end point value)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.221997948534624" CI_START="-0.4419979485346244" EFFECT_SIZE="0.8899999999999999" ESTIMABLE="YES" MEAN_1="2.78" MEAN_2="1.89" ORDER="1" SD_1="2.7" SD_2="2.13" SE="0.6796032779383979" STUDY_ID="STD-Altan-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8405040476655596" CI_START="-2.6405040476655586" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8999999999999995" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.31083053481612544" Q="0.0" RANDOM="NO" SCALE="4.38021555952462" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="18" UNITS="" WEIGHT="100.0" Z="1.0134808870177343">
<NAME>Spinal pain (VAS 10 cm, 0=no pain, 10=severe) (end point value)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8405040476655596" CI_START="-2.6405040476655586" EFFECT_SIZE="-0.8999999999999995" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="4.6" MODIFIED="2012-05-25 10:01:11 -0400" MODIFIED_BY="Junmin Chen" ORDER="61" SD_1="2.9" SD_2="2.3" SE="0.8880285869507974" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>BASMI (VAS-10 cm, 0=severely limited spinal mobility, 10=overall normal) (end point value)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.1526672695931692" CI_START="-0.37266726959316965" EFFECT_SIZE="1.3899999999999997" ESTIMABLE="YES" MEAN_1="6.33" MEAN_2="4.94" ORDER="1" SD_1="2.64" SD_2="1.91" SE="0.8993365610270718" STUDY_ID="STD-Roychowdhury-2002" TOTAL_1="12" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="26" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Spondylitis index (score 0-10, the more severe the disease, the higher the score) (end point value)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.5585488636835487" CI_START="0.9414511363164515" EFFECT_SIZE="2.25" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="0.31" ORDER="1" SD_1="3.3" SD_2="0.82" SE="0.667639239294811" STUDY_ID="STD-Altan-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Enthesis index (score 0-90, the more severe the disease, the higher the score) (end point value)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.3451068967531805" CI_START="0.014893103246819805" EFFECT_SIZE="2.18" ESTIMABLE="YES" MEAN_1="3.68" MEAN_2="1.5" ORDER="1" SD_1="5.27" SD_2="1.95" SE="1.1046666744038498" STUDY_ID="STD-Altan-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>Disappearance of peripheral arthritis (event)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.360268009798731" CI_START="0.6011611300887987" EFFECT_SIZE="1.1911764705882353" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.37296132015996464" LOG_CI_START="-0.22100910781513775" LOG_EFFECT_SIZE="0.07597610617241342" MODIFIED="2010-10-05 06:13:34 -0400" MODIFIED_BY="Junmin Chen" ORDER="1" O_E="0.0" SE="0.3489011695936126" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004" TOTAL_1="17" TOTAL_2="18" VAR="0.12173202614379083" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.3730222216628504" CI_END="0.5519806702503763" CI_START="-0.3055853678030397" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.12319765122366835" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="12" P_CHI2="0.5413617788141882" P_Q="1.0" P_Z="0.5733425911689769" Q="0.0" RANDOM="NO" SCALE="6.057734995689283" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" UNITS="" WEIGHT="100.00000000000001" Z="0.5631355456342749">
<NAME>Patient global assessment (different scales, the more severe the disease, the higher the score) (end point value)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7820086496708407" CI_START="-0.3199625034000828" EFFECT_SIZE="0.23102307313537893" ESTIMABLE="YES" MEAN_1="2.28" MEAN_2="2.05" MODIFIED="2012-05-25 10:06:09 -0400" MODIFIED_BY="Junmin Chen" ORDER="62" SD_1="0.99" SD_2="0.97" SE="0.28112025571978144" STUDY_ID="STD-Altan-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="60.56123111590131"/>
<CONT_DATA CI_END="0.6403958246878552" CI_START="-0.7251488050763713" EFFECT_SIZE="-0.042376490194258015" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="3.4" MODIFIED="2012-05-25 10:06:53 -0400" MODIFIED_BY="Junmin Chen" ORDER="63" SD_1="2.5" SD_2="2.1" SE="0.3483596230684513" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004" TOTAL_1="16" TOTAL_2="17" WEIGHT="39.43876888409871"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.116253165643215" CI_END="0.7470814312070257" CI_START="-1.0284106953902947" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.14066463209163446" ESTIMABLE="YES" I2="75.70606180526951" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="13" P_CHI2="0.042473157163681496" P_Q="1.0" P_Z="0.756135829406241" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.31140805900446744" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" UNITS="" WEIGHT="100.0" Z="0.3105590936373761">
<NAME>Physician global assessment (different scales, the more severe the disease, the higher the score) (end point value)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8422854970409196" CI_START="-0.26196636746056845" EFFECT_SIZE="0.2901595647901756" ESTIMABLE="YES" MEAN_1="2.18" MEAN_2="1.94" ORDER="1" SD_1="1.02" SD_2="0.52" SE="0.28170208055139934" STUDY_ID="STD-Altan-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="52.5008877342868"/>
<CONT_DATA CI_END="0.0635214678810101" CI_START="-1.2972328594259834" EFFECT_SIZE="-0.6168556957724867" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="3.0" MODIFIED="2010-10-05 06:12:16 -0400" MODIFIED_BY="Junmin Chen" ORDER="2" SD_1="1.0" SD_2="2.7" SE="0.3471375846802416" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="47.4991122657132"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="14.863971158040584" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Physical well-being (VAS 10 cm, 0=feeling very well, 10=very bad)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.0511821970650341" CI_START="-2.4511821970650347" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="4.4" MODIFIED="2010-10-05 06:21:08 -0400" MODIFIED_BY="Junmin Chen" ORDER="1" SD_1="3.0" SD_2="2.2" SE="0.8934767224694616" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Morning stiffness duration (units not specified in trial report, we assumed minutes)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="33.00556214810898" CI_START="-2.0655621481089756" EFFECT_SIZE="15.47" ESTIMABLE="YES" MEAN_1="26.25" MEAN_2="10.78" ORDER="1" SD_1="42.5" SD_2="16.26" SE="8.94687978270379" STUDY_ID="STD-Altan-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2012-05-25 10:50:35 -0400" MODIFIED_BY="Junmin Chen" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Severity of morning stiffness (VAS 10 cm, 0=no stiffness, 10=severe)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.435089469645888" CI_START="-1.2350894696458885" EFFECT_SIZE="0.5999999999999996" ESTIMABLE="YES" MEAN_1="3.8" MEAN_2="3.2" MODIFIED="2010-10-05 11:07:55 -0400" MODIFIED_BY="Junmin Chen" ORDER="1" SD_1="3.0" SD_2="2.5" SE="0.9362873420740583" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.17" MODIFIED="2012-05-25 10:59:01 -0400" MODIFIED_BY="Junmin Chen" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="18" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Health assessment questionnaire for spondyloarthropathies (HAQ-S) (0-3, 0=no difficulty, 3=unable to do)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.301062023691445" CI_START="-0.301062023691445" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.5" MODIFIED="2010-10-05 11:09:29 -0400" MODIFIED_BY="Junmin Chen" ORDER="1" SD_1="0.5" SD_2="0.4" SE="0.1536058958563442" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004" TOTAL_1="17" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6501103602165412" CI_END="0.4825969422753477" CI_START="-0.40490797107548365" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.03884448559993203" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2012-05-25 10:59:01 -0400" MODIFIED_BY="Junmin Chen" NO="18" P_CHI2="0.4200734970302926" P_Q="1.0" P_Z="0.8637770404288814" Q="0.0" RANDOM="NO" SCALE="3.9755440046649144" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="38" TOTAL_2="41" UNITS="" WEIGHT="100.0" Z="0.1715681606457897">
<NAME>CRP (change from baseline) (percentage for Altan, ug/ml for others)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.7227066037297879" CI_START="-0.3775162741486079" EFFECT_SIZE="0.17259516479059" ESTIMABLE="YES" MEAN_1="0.17" MEAN_2="0.04" ORDER="1" SD_1="0.82" SD_2="0.65" SE="0.28067425895496384" STUDY_ID="STD-Altan-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="65.06990750034709"/>
<CONT_DATA CI_END="0.5405143248750715" CI_START="-0.961143205145609" EFFECT_SIZE="-0.21031444013526873" ESTIMABLE="YES" MEAN_1="-2.33" MEAN_2="0.94" ORDER="2" SD_1="13.04" SD_2="16.44" SE="0.38308293975439434" STUDY_ID="STD-Roychowdhury-2002" TOTAL_1="12" TOTAL_2="16" WEIGHT="34.93009249965291"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5111865202723382" CI_START="-0.5869306117015392" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.03787204571460051" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" MODIFIED="2012-05-25 10:59:01 -0400" MODIFIED_BY="Junmin Chen" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.8924607633614043" Q="0.0" RANDOM="NO" SCALE="1.4783492767709199" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="25" UNITS="" WEIGHT="100.0" Z="0.13519112571906813">
<NAME>ESR (percentage change from baseline)</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5111865202723382" CI_START="-0.5869306117015392" EFFECT_SIZE="-0.03787204571460051" ESTIMABLE="YES" MEAN_1="0.31" MEAN_2="0.34" ORDER="1" SD_1="0.67" SD_2="0.88" SE="0.2801370690062892" STUDY_ID="STD-Altan-2001" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="269.43717845263336" CI_START="0.9946252688739915" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="16.370370370370374" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="2.430457521909565" LOG_CI_START="-0.0023405115293558916" LOG_EFFECT_SIZE="1.2140585051901047" METHOD="MH" MODIFIED="2012-05-25 10:59:01 -0400" MODIFIED_BY="Junmin Chen" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="0.05044245151813062" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="26" TOTAL_2="25" WEIGHT="100.0" Z="1.9561927563165147">
<NAME>Side effect</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours MTX</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no MTX</GRAPH_LABEL_2>
<DICH_DATA CI_END="269.43717845263336" CI_START="0.9946252688739915" EFFECT_SIZE="16.37037037037037" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.430457521909565" LOG_CI_START="-0.0023405115293558916" LOG_EFFECT_SIZE="1.2140585051901045" ORDER="1" O_E="0.0" SE="1.4290376073865074" STUDY_ID="STD-Altan-2001" TOTAL_1="26" TOTAL_2="25" VAR="2.042148483324954" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="15.619811043133375" CI_START="0.07177470094485149" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="1.1936757758011498" LOG_CI_START="-1.144028608351085" LOG_EFFECT_SIZE="0.024823583725032145" METHOD="MH" MODIFIED="2012-10-03 13:53:33 -0400" MODIFIED_BY="Junmin Chen" NO="21" P_CHI2="1.0" P_Q="1.0" P_Z="0.9667977405292516" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="18" WEIGHT="100.0" Z="0.041624878148074064">
<NAME>Withdrawal for any reason</NAME>
<GROUP_LABEL_1>MTX</GROUP_LABEL_1>
<GROUP_LABEL_2>No MTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="15.619811043133367" CI_START="0.07177470094485151" EFFECT_SIZE="1.0588235294117647" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1936757758011494" LOG_CI_START="-1.144028608351085" LOG_EFFECT_SIZE="0.024823583725032145" ORDER="1" O_E="0.0" SE="1.373179127074352" STUDY_ID="STD-Gonzalez_x002d_Lopez-2004" TOTAL_1="17" TOTAL_2="18" VAR="1.8856209150326797" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-01-22 10:23:17 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-01-22 10:23:17 -0500" MODIFIED_BY="Junmin Chen" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZAAAAMTCAYAAACPBEGTAAAi0klEQVR42u3d7bKsOG9A4bn/m578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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-01-22 10:14:09 -0500" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-01-22 10:14:09 -0500" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUMAAAF0CAIAAAA2LsxFAAAR30lEQVR42u3dsW4U1xfH8ZVoKFxQ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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2013-01-22 11:12:19 -0500" MODIFIED_BY="Junmin Chen">
<APPENDIX ID="APP-01" MODIFIED="2013-01-22 11:08:29 -0500" MODIFIED_BY="Junmin Chen" NO="1">
<TITLE MODIFIED="2008-11-05 14:50:12 -0500" MODIFIED_BY="[Empty name]">Search strategies for the original review</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-22 11:08:29 -0500" MODIFIED_BY="[Empty name]">
<TABLE COLS="2" ROWS="2">
<TR>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>
<B>MEDLINE (Ovid)</B>:<BR/>1 Spondylitis, Ankylosing/<BR/>2 (bechtere$ disease$ or marie-struempell disease$ or rheumatoid spondylitis or spondylarthritis ankylopoietica or ankylo$ spondyl$ or Spin$ Ankylosis or Vertebral Ankylosis).tw.<BR/>3 1 or 2<BR/>4 methotrexate/<BR/>5 (amethopterin$ or mexate or Abitrexate or Ametopterine or Emt#exate or Methylaminopterin$ or Novatrex or Rheumatrex or methotrexate).tw.<BR/>6 methotrexate.rn.<BR/>7 or/4-6<BR/>8 clinical trial.pt.<BR/>9 randomized controlled trial.pt.<BR/>10 tu.fs.<BR/>11 dt.fs.<BR/>12 random$.tw.<BR/>13 (double adj blind$).tw.<BR/>14 placebo$.tw.<BR/>15 or/8-14<BR/>16 3 and 7<BR/>17 15 and 16<BR/>18 from 16 keep 1-62 (62)<BR/>
</P>
</TD>
<TD>
<P>
<B>EMBASE (Ovid)</B>:<BR/>1 Spondylitis, Ankylosing/<BR/>2 (bechtere$ disease$ or marie-struempell disease$ or rheumatoid spondylitis or spondylarthritis ankylopoietica or ankylo$ spondyl$ or Spin$ Ankylosis or Vertebral Ankylosis).tw.<BR/>3 1 or 2<BR/>4 methotrexate/<BR/>5 (amethopterin$ or mexate or Abitrexate or Ametopterine or Emt#exate or Methylaminopterin$ or Novatrex or Rheumatrex or methotrexate).tw.<BR/>6 4 or 5<BR/>7 3 and 6<BR/>8 from 7 keep 1-197<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-01-20 10:25:47 -0500" MODIFIED_BY="Junmin Chen" NO="2">
<TITLE MODIFIED="2011-12-19 13:08:46 -0500" MODIFIED_BY="Junmin Chen">Search strategy for the second version</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-20 10:25:47 -0500" MODIFIED_BY="[Empty name]">
<P>
<B>MEDLINE</B>
</P>
<P>1. Spondylitis, Ankylosing/<BR/>2. (bechtere$ disease$ or marie-struempell disease$ or rheumatoid spondylitis or spondylarthritis ankylopoietica or ankylo$ spondyl$ or Spin$ Ankylosis or Vertebral Ankylosis).tw.<BR/>3. 1 or 2<BR/>4. methotrexate/<BR/>5. (amethopterin$ or mexate or Abitrexate or Ametopterine or Emt#exate or Methylaminopterin$ or Novatrex or Rheumatrex or methotrexate).tw.<BR/>6. methotrexate.rn.<BR/>7. or/4-6<BR/>8. randomized controlled trial.pt.<BR/>9. controlled clinical trial.pt.<BR/>10. randomized controlled trials.sh.<BR/>11. random allocation.sh.<BR/>12. double blind method.sh.<BR/>13. single-blind method.sh.<BR/>14. or/8-13<BR/>15. (animal$ not human).sh.<BR/>16. 14 not 15<BR/>17. clinical trial.pt.<BR/>18. exp clinical trials/<BR/>19. (clin$ adj25 trial$).ti,ab.<BR/>20. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.<BR/>21. placebo$.sh.<BR/>22. placebo$.ti,ab.<BR/>23. random$.ti,ab.<BR/>24. research design.sh.<BR/>25. or/18-24<BR/>26. 25 not 15<BR/>27. 26 not 16<BR/>28. comparative study.sh.<BR/>29. exp evaluation studies/<BR/>30. follow up studies.sh.<BR/>31. prospective studies.sh.<BR/>32. (control$ or prospectiv$ or volunteer$).ti,ab.<BR/>33. or/28-32<BR/>34. 33 not 15<BR/>35. 34 not (16 or 27)<BR/>36. and/3,7,35</P>
<P>
<B>EMBASE</B>
</P>
<P>1. Spondylitis, Ankylosing/<BR/>2. (bechtere$ disease$ or marie-struempell disease$ or rheumatoid spondylitis or spondylarthritis ankylopoietica or ankylo$ spondyl$ or Spin$ Ankylosis or Vertebral Ankylosis).tw.<BR/>3. 1 or 2<BR/>4. methotrexate/<BR/>5. (amethopterin$ or mexate or Abitrexate or Ametopterine or Emt#exate or Methylaminopterin$ or Novatrex or Rheumatrex or methotrexate).tw.<BR/>6. 4 or 5<BR/>7. 3 and 6<BR/>8. random$.ti,ab.<BR/>9. factorial$.ti,ab.<BR/>10. (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>11. placebo$.ti,ab.<BR/>12. (doubl$ adj blind$).ti,ab.<BR/>13. (singl$ adj blind$).ti,ab.<BR/>14. assign$.ti,ab.<BR/>15. allocat$.ti,ab.<BR/>16. volunteer$.ti,ab.<BR/>17. crossover procedure.sh.<BR/>18. double blind procedure.sh.<BR/>19. randomized controlled trial.sh.<BR/>20. single blind procedure.sh.<BR/>21. or/8-20<BR/>22. exp animal/ or nonhuman/ or exp animal experiment/<BR/>23. exp human/<BR/>24. 22 and 23<BR/>25. 22 not 24<BR/>26. 21 not 25<BR/>27. 7 and 26</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2012-07-25 11:44:52 -0400" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2012-01-03 11:53:40 -0500" MODIFIED_BY="[Empty name]">Search strategies for the third (current) version review</TITLE>
<APPENDIX_BODY MODIFIED="2012-07-25 11:44:52 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Ovid MEDLINE</B>
</P>
<P>1. Spondylitis, Ankylosing/</P>
<P>2. (ankylos$ or spondyl$).tw.</P>
<P>3. (bekhterev$ or bechterew$).tw.</P>
<P>4. (Marie adj struempell$).tw.</P>
<P>5. or/1-4</P>
<P>6. Methotrexate/</P>
<P>7. Methotrexate.tw.</P>
<P>8. amet?opterine.tw.</P>
<P>9. mexate.tw.</P>
<P>10. Abitrexate.tw.</P>
<P>11. A Met?opterine$.tw.</P>
<P>12. Antifolan.tw.</P>
<P>13. Emt?exate.tw.</P>
<P>14. Enthexate.tw.</P>
<P>15. Farmitrexate.tw.</P>
<P>16. Folex.tw.</P>
<P>17. Ledertrexate.tw.</P>
<P>18. Methoblastin.tw.</P>
<P>19. Methohexate.tw.</P>
<P>20. Methotrate.tw.</P>
<P>21. Methylaminopterin.tw.</P>
<P>22. Metotrexat$.tw.</P>
<P>23. Mtx.tw.</P>
<P>24. Novatrex.tw.</P>
<P>25. Rheumatrex.tw.</P>
<P>26. or/6-25</P>
<P>27. randomized controlled trial.pt.</P>
<P>28. controlled clinical trial.pt.</P>
<P>29. randomized.ab.</P>
<P>30. placebo.ab.</P>
<P>31. drug therapy.fs.</P>
<P>32. randomly.ab.</P>
<P>33. trial.ab.</P>
<P>34. groups.ab.</P>
<P>35. or/27-34</P>
<P>36. (animals not (humans and animals)).sh.</P>
<P>37. 35 not 36</P>
<P>38. and/5,26,37</P>
<P> </P>
<P>
<B>Ovid EMBASE</B>
</P>
<P>1. ankylosing spondylitis/</P>
<P>2. (ankylos$ or spondyl$).tw.</P>
<P>3. (bekhterev$ or bechterew$).tw.</P>
<P>4. (Marie adj struempell$).tw.</P>
<P>5. or/1-4</P>
<P>6. methotrexate/</P>
<P>7. Methotrexate.tw.</P>
<P>8. mexate.tw.</P>
<P>9. Abitrexate.tw.</P>
<P>10. Amet?opterine.tw.</P>
<P>11. mexate.tw.</P>
<P>12. Abitrexate.tw.</P>
<P>13. A Met?opterine.tw.</P>
<P>14. Antifolan.tw.</P>
<P>15. Emt?exate.tw.</P>
<P>16. Enthexate.tw.</P>
<P>17. Farmitrexate.tw.</P>
<P>18. Folex.tw.</P>
<P>19. Ledertrexate.tw.</P>
<P>20. Methoblastin.tw.</P>
<P>21. Methohexate.tw.</P>
<P>22. Methotrate.tw.</P>
<P>23. Methylaminopterin.tw.</P>
<P>24. Metotrexat$.tw.</P>
<P>25. Mtx.tw.</P>
<P>26. Novatrex.tw.</P>
<P>27. Rheumatrex.tw.</P>
<P>28. or/6-27</P>
<P>29. (random$ or placebo$).ti,ab.</P>
<P>30. ((single$ or double$ or triple$ or treble$) and (blind$ or mask$)).ti,ab.</P>
<P>31. controlled clinical trial$.ti,ab.</P>
<P>32. RETRACTED ARTICLE/</P>
<P>33. or/29-32</P>
<P>34. (animal$ not human$).sh,hw.</P>
<P>35. 33 not 34</P>
<P>36. 28 and 35</P>
<P>37. and/5,28,36</P>
<P> </P>
<P>
<B>The Cochrane Library via Ovid EBM Reviews</B>
</P>
<P>1. (ankylos$ or spondyl$).tw.</P>
<P>2. (bekhterev$ or bechterew$).tw.</P>
<P>3. (Marie adj struempell$).tw.</P>
<P>4. or/1-3</P>
<P>5. Methotrexate.tw.</P>
<P>6. amet?opterine.tw.</P>
<P>7. mexate.tw.</P>
<P>8. Abitrexate.tw.</P>
<P>9. A Met?opterine$.tw.</P>
<P>10. Antifolan.tw.</P>
<P>11. Emt?exate.tw.</P>
<P>12. Enthexate.tw.</P>
<P>13. Farmitrexate.tw.</P>
<P>14. Folex.tw.</P>
<P>15. Ledertrexate.tw.</P>
<P>16. Methoblastin.tw.</P>
<P>17. Methohexate.tw.</P>
<P>18. Methotrate.tw.</P>
<P>19. Methylaminopterin.tw.</P>
<P>20. Metotrexat$.tw.</P>
<P>21. Mtx.tw.</P>
<P>22. Novatrex.tw.</P>
<P>23. Rheumatrex.tw.</P>
<P>24. or/5-23</P>
<P>25. 4 and 24</P>
<P>
<B> </B>
</P>
<P>
<B>CINAHL</B>
</P>
<P>S29 S7 and S28</P>
<P>S28 S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27</P>
<P>S27 TI Rheumatrex OR AB Rheumatrex</P>
<P>S26 TI Novatrex OR AB Novatrex</P>
<P>S25 TI Mtx OR AB Mtx</P>
<P>S24 TI Metotrexat* OR AB Metotrexat*</P>
<P>S23 TI Methylaminopterin OR AB Methylaminopterin</P>
<P>S22 TI Methotrate OR AB Methotrate</P>
<P>S21 TI Methohexate OR AB Methohexate</P>
<P>S20 TI Methoblastin OR AB Methoblastin</P>
<P>S19 TI Ledertrexate OR AB Ledertrexate</P>
<P>S18 TI Folex OR AB Folex</P>
<P>S17 TI Farmitrexate OR AB Farmitrexate</P>
<P>S16 TI Enthexate OR AB Enthexate</P>
<P>S15 TI Emt?exate OR AB Emt?exate</P>
<P>S14 TI Antifolan OR AB Antifolan</P>
<P>S13 TI A Met?opterine OR AB A Met?opterine</P>
<P>S12 TI Abitrexate OR AB Abitrexate</P>
<P>S11 TI mexate OR AB mexate<BR/>S10 TI amet?opterine OR AB amet?opterine</P>
<P>S9 TI Methotrexate OR AB</P>
<P>S8 (MH "Methotrexate")</P>
<P>S7 S1 or S2 or S3 or S4 or S5 or S6</P>
<P>S6 TI Marie struempell* OR AB Marie struempell*</P>
<P>S5 TI bechterew* OR AB bechterew*</P>
<P>S4 TI bekhterev* OR AB bekhterev*</P>
<P>S3 TI spondyl* OR AB spondyl*</P>
<P>S2 TI ankylos* OR AB ankylos*</P>
<P>S1 (MH "Spondylitis, Ankylosing")</P>
<P> <B> </B>
</P>
<P>
<B>Scopus</B>
</P>
<P>#1 (TITLE-ABS-KEY(ankylos*) OR TITLE-ABS-KEY(spondyl*) OR TITLE-ABS-KEY(bekhterev*) OR TITLE-ABS-KEY(bechterew*) OR TITLE-ABS-KEY(marie struempell*))</P>
<P>#2 (TITLE-ABS-KEY(methotrexate) OR TITLE-ABS-KEY(amet?opterine) OR TITLE-ABS-KEY(mexate) OR TITLE-ABS-KEY(abitrexate) OR TITLE-ABS-KEY("A Met?opterine") OR TITLE-ABS-KEY(antifolan) OR TITLE-ABS-KEY(emt?exate) OR TITLE-ABS-KEY(enthexate) OR TITLE-ABS-KEY(farmitrexate) OR TITLE-ABS-KEY(folex) OR TITLE-ABS-KEY(ledertrexate) OR TITLE-ABS-KEY(methoblastin) OR TITLE-ABS-KEY(methohexate) OR TITLE-ABS-KEY(methotrate) OR TITLE-ABS-KEY(methylaminopterin) OR TITLE-ABS-KEY(metotrexat*) OR TITLE-ABS-KEY(mtx) OR TITLE-ABS-KEY(novatrex) OR TITLE-ABS-KEY(rheumatrex))</P>
<P>#3 #1 AND #2</P>
<P>#4 Limit to Conference Paper</P>
<P> </P>
<P>
<B>World Health Organization International Clinical Trials Registry Platform</B>
</P>
<P>ankylos* OR spondyl* OR bekhterev* OR bechterew* OR marie struempell* in Condition AND methotrexate in Intervention</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2013-01-22 11:08:58 -0500" MODIFIED_BY="Junmin Chen" NO="4">
<TITLE MODIFIED="2011-12-19 13:42:53 -0500" MODIFIED_BY="Junmin Chen">Search result for the third version</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-22 11:08:58 -0500" MODIFIED_BY="Junmin Chen">
<P>
<B>Methotrexate for Ankylosing Spondylitis Update January 2011</B>
</P>
<P>

</P>
<P>
<B>All databases searched January 11, 2011</B>
</P>
<P> </P>
<TABLE COLS="4" ROWS="8">
<TR>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Database</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Dates searched</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Number of references retrieved</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="TOP">
<P>
<B>Number after duplicates removed</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>MEDLINE (Ovid)</B>
</P>
<P>and</P>
<P> </P>
<P>Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations</P>
</TD>
<TD VALIGN="TOP">
<P>2005 to December Week 4 2010</P>
<P>January 10, 2011</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
<P/>
<P>129</P>
</TD>
<TD ALIGN="CENTER">
<P>129</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Embase (Ovid)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2005 to 2011 Week 01</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>112</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>80</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>CENTRAL, </B>part of <I>The Cochrane Library</I> (via Ovid EBM Reviews)</P>
<P>
<B> </B>
</P>
<P>
<B>DARE</B>, part of <I>The Cochrane Library</I> (via Ovid EBM Reviews)</P>
<P>
<B> </B>
</P>
<P>
<B>HTA Database</B>, part of <I>The Cochrane Library </I>(via Ovid EBM Reviews)</P>
<P>
<B> </B>
</P>
<P>
<B>NHS EED</B>, part of <I>The Cochrane Library</I> (via Ovid EBM Reviews)</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>4th Quarter 2010</P>
<P> </P>
<P/>
<P>4th Quarter 2010</P>
<P> </P>
<P/>
<P>1st Quarter 2011</P>
<P> </P>
<P> </P>
<P>

</P>
<P>1st Quarter 2011</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6</P>
<P> </P>
<P> </P>
<P>5</P>
<P> </P>
<P> </P>
<P>0</P>
<P> </P>
<P> </P>
<P>

</P>
<P>0</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0</P>
<P> </P>
<P> </P>
<P>4</P>
<P> </P>
<P> </P>
<P>0</P>
<P> </P>
<P> </P>
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>CINAHL (EBSCOHost)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2005 to January 2011</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>28</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>11</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Scopus</B>
</P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>2005 to January 11, 2011</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>47</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>44</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>World Health Organization International Clinical Trials Registry Platform</B>
</P>
<P>
<B>http://www.who.int/ictrp/en/</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Searched January 11, 2011</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P/>
<P>0</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>0</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>All databases</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> Totals</B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>
<B>327</B>
</P>
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>
<B>268</B>
</P>
</TD>
</TR>
</TABLE>
<P> <B>Search:  Methotrexate for Ankylosing Spondylitis &#8211; May 2012 Update</B>
</P>
<P>
<B> </B>
</P>
<TABLE COLS="4" ROWS="8">
<TR>
<TH VALIGN="TOP">
<P>Database and coverage</P>
</TH>
<TH VALIGN="TOP">
<P>Search Date</P>
</TH>
<TH VALIGN="TOP">
<P>#Results</P>
<P/>
</TH>
<TH VALIGN="TOP">
<P>Results with</P>
<P>duplicates removed</P>
</TH>
</TR>
<TR>
<TD>
<P>
<I>The Cochrane Library</I>
</P>
<P> </P>
<P>
<B>Issue 6 of 12, June </B>
</P>
<P>
<B>2012</B>
<BR/>
</P>
<P>
<A HREF="http://www.cochranelibrary.com/">www.cochranelibrary.com</A>
</P>
<P>Cochrane Controlled Trials Register</P>
<P>(CENTRAL)</P>
</TD>
<TD>
<P/>
<P>June 25,</P>
<P>2012</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>OVID MEDLINE, Dec 2011-</P>
</TD>
<TD>
<P>June 25,</P>
<P>2012</P>
</TD>
<TD ALIGN="CENTER">
<P>26</P>
</TD>
<TD ALIGN="CENTER">
<P>19</P>
</TD>
</TR>
<TR>
<TD>
<P>Ebsco CINAHL, Dec 2011-</P>
</TD>
<TD>
<P>June 25,</P>
<P>2012</P>
</TD>
<TD ALIGN="CENTER">
<P>8</P>
</TD>
<TD ALIGN="CENTER">
<P>7</P>
</TD>
</TR>
<TR>
<TD>
<P>OVID EMBASE  Dec 2011-</P>
</TD>
<TD>
<P>June 25,</P>
<P>2012</P>
</TD>
<TD ALIGN="CENTER">
<P>17</P>
</TD>
<TD ALIGN="CENTER">
<P>15</P>
</TD>
</TR>
<TR>
<TD>
<P>Scopus Dec 2011-</P>
</TD>
<TD>
<P>June 25,</P>
<P>2012</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
</TD>
</TR>
<TR>
<TD>
<P>WHO ICTRP  2011-</P>
</TD>
<TD>
<P>June 25,</P>
<P>2012</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P> <B>All databases</B>
</P>
</TD>
<TD>
<P>
<B>Totals</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>66</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>56</B>
</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2013-01-22 11:09:01 -0500" MODIFIED_BY="Junmin Chen" NO="5">
<TITLE MODIFIED="2011-02-05 07:00:11 -0500" MODIFIED_BY="Junmin Chen">Risk of bias assessment criteria</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-22 11:09:01 -0500" MODIFIED_BY="Junmin Chen">
<TABLE COLS="2" ROWS="4">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>SEQUENCE GENERATION </B>
</P>
<P>
<B>Was the allocation sequence adequately generated? [Short form: <I>Adequate sequence generation</I>?] </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'YES' (i.e. low risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>The investigators describe a random component in the sequence generation process such as:</P>
<UL>
<LI>Referring to a random number table;</LI>
<LI>Using a computer random number generator;</LI>
<LI>Coin tossing;</LI>
<LI>Shuffling cards or envelopes;</LI>
<LI>Throwing dice;</LI>
<LI>Drawing of lots;</LI>
<LI>Minimization*.</LI>
</UL>
<P/>
<P>*Minimization may be implemented without a random element, and this is considered to be equivalent to being random.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'NO' (i.e. high risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some systematic, non-random approach, for example:</P>
<UL>
<LI>Sequence generated by odd or even date of birth;</LI>
<LI>Sequence generated by some rule based on date (or day) of admission;</LI>
<LI>Sequence generated by some rule based on hospital or clinic record number.</LI>
</UL>
<P> </P>
<P>Other non-random approaches happen much less frequently than the systematic approaches mentioned above and tend to be obvious. They usually involve judgement or some method of non-random categorization of participants, for example:</P>
<UL>
<LI>Allocation by judgement of the clinician;</LI>
<LI>Allocation by preference of the participant;</LI>
<LI>Allocation based on the results of a laboratory test or a series of tests;</LI>
<LI>Allocation by availability of the intervention.</LI>
</UL>
</TD>
</TR>
<TR>
<TD>
<P>Criteria for the judgement of 'UNCLEAR' (uncertain risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information about the sequence generation process to permit judgement of 'Yes' or 'No'.</P>
</TD>
</TR>
</TABLE>
<P> </P>
<TABLE COLS="2" ROWS="4">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>ALLOCATION CONCEALMENT </B>
</P>
<P>
<B>Was allocation adequately concealed? [Short form: <I>Allocation concealment</I>?] </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'YES' (i.e. low risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Participants and investigators enrolling participants could not foresee assignment because of one of the following, or an equivalent method, was used to conceal allocation:</P>
<UL>
<LI>Central allocation (including telephone, web-based, and pharmacy-controlled, randomization);</LI>
<LI>Sequentially numbered drug containers of identical appearance;</LI>
<LI>Sequentially numbered, opaque, sealed envelopes.</LI>
</UL>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'NO' (i.e. high risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on:</P>
<UL>
<LI>Using an open random allocation schedule (e.g. a list of random numbers);</LI>
<LI>Assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered);</LI>
<LI>Alternation or rotation;</LI>
<LI>Date of birth;</LI>
<LI>Case record number;</LI>
<LI>Any other explicitly unconcealed procedure.</LI>
</UL>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'UNCLEAR' (uncertain risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to permit judgement of 'Yes' or 'No'. This is usually the case if the method of concealment is not described or not described in sufficient detail to allow a definite judgement ¨C for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.</P>
</TD>
</TR>
</TABLE>
<P> </P>
<TABLE COLS="2" ROWS="4">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>BLINDING OF PARTICIPANTS, PERSONNEL AND OUTCOME ASSESSORS </B>
</P>
<P>
<B>Was knowledge of the allocated interventions adequately prevented during the study? [Short form: <I>Blinding</I>?] </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'YES' (i.e. low risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<UL>
<LI>No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding;</LI>
<LI>Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken;</LI>
<LI>Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of others unlikely to introduce bias.</LI>
</UL>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'NO' (i.e. high risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<UL>
<LI>No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding;</LI>
<LI>Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken;</LI>
<LI>Either participants or some key study personnel were not blinded, and the non-blinding of others likely to introduce bias.</LI>
</UL>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'UNCLEAR' (uncertain risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<UL>
<LI>Insufficient information to permit judgement of 'Yes' or 'No';</LI>
<LI>The study did not address this outcome.</LI>
</UL>
<P> </P>
</TD>
</TR>
</TABLE>
<P> </P>
<TABLE COLS="2" ROWS="4">
<TR>
<TD COLSPAN="2">
<P>
<B>INCOMPLETE OUTCOME DATA </B>
</P>
<P>
<B>Were incomplete outcome data adequately addressed? [Short form: <I>Incomplete outcome data addressed</I>?] </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'YES'</P>
<P>(i.e. low risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<UL>
<LI>No missing outcome data;</LI>
<LI>Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias);</LI>
<LI>Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups;</LI>
<LI>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate;</LI>
<LI>For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size;</LI>
<LI>Missing data have been imputed using appropriate methods.</LI>
</UL>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'NO' (i.e. high risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<UL>
<LI>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups;</LI>
<LI>For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate;</LI>
<LI>For continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size;</LI>
<LI>'As-treated' analysis done with substantial departure of the intervention received from that assigned at randomization;</LI>
<LI>Potentially inappropriate application of simple imputation.</LI>
</UL>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'UNCLEAR' (uncertain risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<UL>
<LI>Insufficient reporting of attrition/exclusions to permit judgement of 'Yes' or 'No' (e.g. number randomized not stated, no reasons for missing data provided);</LI>
<LI>The study did not address this outcome.</LI>
</UL>
<P> </P>
</TD>
</TR>
</TABLE>
<P/>
<TABLE COLS="2" ROWS="4">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>SELECTIVE OUTCOME REPORTING </B>
</P>
<P>
<B>Are reports of the study free of suggestion of selective outcome reporting? [Short form: <I>Free of selective reporting</I>?] </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'YES' (i.e. low risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Any of the following:</P>
<UL>
<LI>The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way;</LI>
<LI>The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</LI>
</UL>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'NO' (i.e. high risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Any one of the following:</P>
<UL>
<LI>Not all of the study's pre-specified primary outcomes have been reported;</LI>
<LI>One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-specified;</LI>
<LI>One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect);</LI>
<LI>One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis;</LI>
<LI>The study report fails to include results for a key outcome that would be expected to have been reported for such a study.</LI>
</UL>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'UNCLEAR' (uncertain risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to permit judgement of 'Yes' or 'No'. It is likely that the majority of studies will fall into this category.</P>
</TD>
</TR>
</TABLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>
<B>OTHER POTENTIAL THREATS TO VALIDITY </B>
</P>
<P>
<B>Was the study apparently free of other problems that could put it at a risk of bias? [Short form: <I>Free of other bias</I>?] </B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for a judgement of 'YES' (i.e. low risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'NO' (i.e. high risk of bias).</P>
</TD>
<TD VALIGN="TOP">
<P>There is at least one important risk of bias. For example, the study:</P>
<UL>
<LI>Had a potential source of bias related to the specific study design used; or</LI>
<LI>Stopped early due to some data-dependent process (including a formal-stopping rule); or</LI>
<LI>Had extreme baseline imbalance; or</LI>
<LI>Has been claimed to have been fraudulent; or</LI>
<LI>Had some other problem.</LI>
</UL>
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Criteria for the judgement of 'UNCLEAR' (uncertain risk of bias).Search</P>
</TD>
<TD>
<P>There may be a risk of bias, but there is either:</P>
<UL>
<LI>Insufficient information to assess whether an important risk of bias exists; or</LI>
<LI>Insufficient rationale or evidence that an identified problem will introduce bias</LI>
</UL>
</TD>
</TR>
</TABLE>
<P>  </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2013-01-22 11:12:19 -0500" MODIFIED_BY="Junmin Chen" NO="6">
<TITLE MODIFIED="2011-09-24 10:17:43 -0400" MODIFIED_BY="Junmin Chen">Sample data collection form for assessment of risk of bias</TITLE>
<APPENDIX_BODY MODIFIED="2013-01-22 11:12:19 -0500" MODIFIED_BY="Junmin Chen">
<TABLE COLS="3" ROWS="10">
<TR>
<TH VALIGN="TOP">
<P>
<B>DOMAIN</B>
</P>
</TH>
<TH VALIGN="TOP">
<P>JUDGEMENT (YES - low risk; NO - high risk; or UNCLEAR)</P>
</TH>
<TH VALIGN="TOP">
<P>REASON FOR JUDGEMENT (copy and paste directly from text of trial)</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Was the allocation sequence adequately generated?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Was allocation adequately concealed?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Was knowledge of the allocated interventions adequately prevented during the study?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Blinding of personnel</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Blinding of participants</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Blinding of outcome assessors</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Were incomplete outcome data adequately addressed?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Are reports of the study free of suggestion of selective outcome reporting</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Was the study apparently free of other problems that could put it at a risk of bias?</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2010-10-02 03:50:08 -0400" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;No study included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;No study included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;7 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;320 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;320 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;324 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;1 additional record identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;313 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;7 full-text articles excluded, with reasons&lt;/p&gt;&lt;p&gt;-2 duplicate publications&lt;/p&gt;&lt;p&gt;-2 not RCTs&lt;/p&gt;&lt;p&gt;-3 trials with infliximab&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>